WO2019022520A1 - 핵산 복합체 페어, 경쟁 구조체, 이를 이용한 pcr 키트 - Google Patents
핵산 복합체 페어, 경쟁 구조체, 이를 이용한 pcr 키트 Download PDFInfo
- Publication number
- WO2019022520A1 WO2019022520A1 PCT/KR2018/008444 KR2018008444W WO2019022520A1 WO 2019022520 A1 WO2019022520 A1 WO 2019022520A1 KR 2018008444 W KR2018008444 W KR 2018008444W WO 2019022520 A1 WO2019022520 A1 WO 2019022520A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- unit
- tag
- acid complex
- label
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/10—Nucleotidyl transfering
- C12Q2521/101—DNA polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/30—Oligonucleotides characterised by their secondary structure
- C12Q2525/301—Hairpin oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/101—Temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/10—Detection mode being characterised by the assay principle
- C12Q2565/101—Interaction between at least two labels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/10—Detection mode being characterised by the assay principle
- C12Q2565/101—Interaction between at least two labels
- C12Q2565/1015—Interaction between at least two labels labels being on the same oligonucleotide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/60—Detection means characterised by use of a special device
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Definitions
- An embodiment relates to a nucleic acid complex pair.
- An embodiment relates to a method for detecting a target using a nucleic acid complex pair.
- Embodiments relate to competing structures used with nucleic acid complex pairs.
- An embodiment relates to a PCR kit comprising a nucleic acid complex pair and a competitive construct.
- Molecular diagnostics is a field of diagnosing diseases by analyzing genes, which is the highest growth rate among the in vitro diagnostic fields.
- the rapid spread of new viruses which are presumed to be due to environmental pollution and climate change, has the greatest accuracy of diagnosis in the field of in vitro diagnostics and the advantage of being able to quickly detect the presence of new viruses
- Much research on molecular diagnostics continues.
- DNA sequencing and polymerase chain reaction are mainly used. Since the cost of equipment for DNA sequencing is still high and the target can not be detected more rapidly than the PCR test, the majority of small and medium hospitals, large hospitals and health examination centers The PCR test for the sample is carried out to diagnose the disease of the patient.
- one kind of target is detected in one PCR tube, or a plurality of fluorescence channels are designed to emit light in accordance with presence or absence of different targets using a probe, and one PCR It was possible to simultaneously perform target detection of the kind corresponding to the number of fluorescent channels in the tube.
- the PCR method for detecting one kind of target in one PCR tube waste of the reagent is serious, and the time required and the labor cost involved are considerable.
- the PCR method using a probe designed to emit light in accordance with the presence or absence of different targets of a plurality of fluorescent channels has a problem that the design of the probe is difficult and the reactivity is poor.
- the example provides a simple designed nucleic acid complex pair that can be used for target detection in a sample.
- An embodiment provides a PCR kit comprising a nucleic acid complex pair capable of detecting plural kinds of targets per fluorescence channel.
- a first nucleic acid complex comprising a first determinant as a primer for a first target DNA, and a first tag portion; And a second nucleic acid complex comprising a first nucleic acid complex and a second nucleic acid complex having a sequence complementary to the first tag portion, and a second crystal portion serving as a primer for the second target DNA, and a second tag portion having a sequence complementary to the first tag portion.
- PCR comprising: a first additional sequence having a sequence complementary to a nucleotide sequence of at least a part of the nucleotide sequence of the first determinant; And a second additional sequence part having a sequence complementary to a base sequence of at least a part of the base sequence of the first tag part.
- a nucleic acid complex pair according to an embodiment can perform target detection in a sample using a dissociation temperature of a tag having a complementary binding.
- the PCR kit according to the embodiment can be used to perform a plurality of types of target detection per fluorescence channel, including a plurality of kinds of nucleic acid conjugate pairs designed to differentiate the dissociation temperature of a tag.
- FIG. 1 is a diagram for explaining a nucleic acid complex 1 according to an embodiment of the present application.
- FIG. 2 is a diagram for explaining the positional relationship among the components of the nucleic acid complex 1 according to one embodiment of the present application.
- 3 is a view for explaining the nucleic acid complex 1 according to the first embodiment of the present application.
- FIG. 4 is a diagram for explaining the positional relationship among the components of the nucleic acid complex 1 according to one embodiment of the present application.
- 5 is a diagram for explaining the nucleic acid complex 1 according to the second embodiment of the present application.
- FIG. 6 is a diagram for explaining the positional relationship among the components of the nucleic acid complex 1 according to one embodiment of the present application.
- FIG. 7 is a diagram for explaining the nucleic acid complex 1 according to the third embodiment of the present application.
- FIG. 8 is a diagram for explaining the positional relationship among the components of the nucleic acid complex 1 according to one embodiment of the present application.
- FIG 9 is a view for explaining a nucleic acid complex pair 10 according to an embodiment of the present application.
- FIGS. 10 and 11 are views for explaining the operation of the first determination unit 111 and the second determination unit 121 according to one embodiment of the present application.
- FIG. 12 is a view for explaining the direction in which the first nucleic acid complex 110 and the second nucleic acid complex 120 are combined according to an embodiment of the present invention.
- FIG 13 is a view for explaining the coupling between the first tag portion 112 and the second tag portion 122 according to the embodiment of the present application.
- FIG 14 is a view for explaining the operation of the first label portion 113 and the second label portion 123 according to an embodiment of the present application.
- F 15 is a graph of a fluorescence value (F) per wavelength band WL according to the coupling action between the first label portion 113 and the second label portion 123, according to an embodiment of the present application.
- 16 is a diagram for explaining a nucleic acid complex 1 capable of performing PCR clamping, according to an embodiment of the present application.
- 17 is a diagram for explaining a PCR step according to an embodiment of the present application.
- 18 and 19 are diagrams for explaining the operation of the nucleic acid complex 1 capable of performing PCR clamping according to one embodiment of the present application.
- 20 is a diagram for explaining a nucleic acid complex pair 10 according to an embodiment of the present application.
- 21 is a diagram for explaining a pairing operation of the nucleic acid complex pair 10 according to an embodiment of the present application.
- 22 is a diagram for explaining a nucleic acid complex pair 10 according to an embodiment of the present application.
- FIGS. 23 and 24 are views for explaining the formation of a secondary structure of a structure coupled with the first crystallization part 111 and the second crystallization part 121, according to an embodiment of the present application.
- 25 and 26 are views for explaining a process of forming a structure including the first crystal section 111 and the second crystal section 121 according to an embodiment of the present application.
- FIGS. 27 and 28 are views for explaining the formation of a secondary structure of a structure including the first crystallization part 111 and the second crystallization part 121, according to one embodiment of the present application.
- 29 and 30 are diagrams illustrating the formation of a secondary structure of a nucleic acid construct comprising a nucleic acid complex pair 10 according to an embodiment of the present application.
- 31 is a view for explaining the formation of a secondary structure of a nucleic acid construct according to an embodiment of the present application.
- 32 is a view for explaining a nucleic acid complex pair 10 according to an embodiment of the present application.
- FIG. 33 is a diagram for explaining a post-PCR detection step according to an embodiment of the present application.
- FIG. 33 is a diagram for explaining a post-PCR detection step according to an embodiment of the present application.
- FIG. 36 is a view for explaining confirmation of the concentration of a target nucleic acid present in the unit cell UC according to an embodiment of the present application.
- FIG. 37 is a view for explaining a competitive structure 2 according to an embodiment of the present application.
- 38 to 40 are diagrams for explaining the operation of the competitive structure 2 according to the embodiment of the present application.
- 41 is a diagram for explaining PCR results using the nucleic acid conjugate pair 10 and the competitive structure 2 according to one embodiment of the present application.
- FIG. 42 is a graph of a fluorescence value versus temperature for one fluorescence channel and a graph of the rate of change of fluorescence value according to temperature-temperature according to an embodiment of the present application.
- FIG. 43 is a diagram for explaining the results of an experiment for identifying at least four kinds of target nucleic acids present in a unit cell UC according to an embodiment of the present application.
- 44 and 45 are diagrams for explaining utilization of the nucleic acid complex pair 10 according to the seventh embodiment of the present application.
- 46 is a diagram for explaining target nucleic acid detection in which a nucleic acid conjugate pair 10 and a probe complex 600 according to an embodiment of the present application are used.
- 47 is a view for explaining a probe complex 610 according to an embodiment of the present application.
- 48 and 49 are views for explaining PCR of a solution provided in a unit cell UC including a probe complex 610 and a nucleic acid complex pair 10 according to an embodiment of the present application.
- 50 is a view for explaining a negative change rate graph of a fluorescence value according to temperature-temperature according to an embodiment of the present application.
- FIG. 51 is a view for explaining a result of an experiment for identifying at least four kinds of target nucleic acids present in a unit cell UC according to an embodiment of the present application.
- FIG 52 is a view for explaining the probe complex 620 according to the second embodiment of the present application.
- 53 and 54 are views for explaining the PCR of the solution provided in the unit cell UC including the probe complex 620 and the nucleic acid complex pair 10 according to the embodiment of the present application.
- FIG. 55 is a view for explaining a negative change rate graph of a fluorescence value according to temperature-temperature according to an embodiment of the present application.
- 56 is a diagram for explaining a preparation step of a sample when the nucleic acid conjugate pair 10 according to an embodiment of the present application is used for digital PCR.
- 57 is a view for explaining a unit cell (UC) in a digital PCR according to an embodiment of the present application.
- 58 is a diagram for explaining the operation in digital PCR using the nucleic acid conjugate pair 10 according to an embodiment of the present application.
- FIG. 59 is a diagram for explaining a method of performing a dissociation curve detection step (S6000) in digital PCR according to an embodiment of the present application.
- 60 is a block diagram of a PCR device 2000 according to an embodiment of the present application.
- 61 is a flowchart for explaining the operation (S7000) of the PCR device 2000 according to an embodiment of the present application.
- a nucleic acid construct comprising: a first nucleic acid complex comprising a first crystallization part and a second tag part; And a second nucleic acid complex comprising a second crystal portion and a second tag portion, wherein the first determining portion includes a forward primer for a first target DNA, and the second determining portion comprises: And a reverse primer for the first target DNA, wherein the first tag comprises a base sequence complementary to the base sequence of the second tag, and the second tag comprises a base complementary to the base sequence of the first tag, , ≪ / RTI > nucleic acid complex pairs can be provided.
- the first determinant may be a nucleic acid selected from the group consisting of Deoxyribonucleic acid (RNA), Ribonucleic acid (RNA), Peptide nucleic acid (PNA), Locked Nucleic Acid (LNA), Bridged nucleic acid (BNA), Hexose nucleic acid wherein the second crystal unit is composed of DNA (Deoxyribonucleic acid), RNA (Ribonucleic acid), PNA (Peptide nucleic acid), LNA
- RNA complex pair consisting of a nucleic acid molecule, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, May be provided.
- the first tag unit may be a nucleic acid tag such as DNA (Deoxyribonucleic acid), Ribonucleic acid (RNA), Peptide nucleic acid (PNA), Locked Nucleic Acid (LNA), Bridged nucleic acid (BNA), Hexose nucleic acid wherein the second tag portion comprises DNA (Deoxyribonucleic acid), Ribonucleic acid (RNA), Peptide nucleic acid (PNA), LNA
- a nucleic acid complex pair consisting of a nucleic acid molecule, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, a nucleic acid, May be provided.
- first nucleic acid complex comprises a first label moiety and the second nucleic acid complex comprises a second label moiety and wherein the first label moiety is capable of providing energy to the second label moiety .
- the first label portion may be selected from the group consisting of FAM, JOE, TET, HEX, VIC, Oregon Green, TAMRA, ROX, Cyanine-3, Cyanine-3.5, Cyanine-5, Cyanine-5.5, Aequorin, Cyan Fluorescent Protein, CFP). ≪ / RTI >
- the second label portion is a material that absorbs the first light emitted from the first label portion and absorbs the first light emitted from the first label portion, May be provided.
- the first label portion may provide energy to the second label portion when the first tag portion and the second tag portion complementarily engage.
- first tag portion is positioned between the first determination portion and the first label portion and the second tag portion is positioned between the second determination portion and the second label portion .
- first label portion is positioned between the first determination portion and the first tag portion and the second tag portion is always positioned between the second determination portion and the second label portion .
- a first connection portion is located between the first determination portion and the first tag portion, and a second connection portion is located between the second determination portion and the second tag portion.
- first connection unit includes a PCR blocker for preventing generation of an amplification product for the first tag unit
- second connection unit includes a PCR blocker for preventing generation of an amplification product for the second tag unit
- nucleic acid complex pair is used to perform a nucleic acid sequence amplification reaction (PCR), and the nucleic acid sequence amplification reaction is performed to amplify at least a partial sequence of the first target DNA.
- PCR nucleic acid sequence amplification reaction
- the nucleic acid complex pair may be provided with a nucleic acid complex pair used for performing digital PCR.
- the length of the nucleotide sequence of the first tag portion may be shorter than the length of the nucleotide sequence of the second tag portion.
- Some base sequences of the base sequence of the first tag portion may be provided with a nucleic acid complex pair that is the same as some base sequences of the base sequence of the first crystal portion or some base sequences of the base sequence of the second crystal portion.
- a kit for PCR comprising the nucleic acid complex pair according to claim 1 can be provided.
- a DNA polymerase, a coenzyme involved in PCR, and a buffer for adjusting pH and / or salt concentration are included in the DNA polymerase, a coenzyme involved in PCR, and a buffer for adjusting pH and / or salt concentration.
- a first nucleic acid complex comprising a first determinant as a primer for a first target DNA, and a first tag portion; And a second nucleic acid complex comprising a first nucleic acid complex and a second nucleic acid complex having a sequence complementary to the first tag portion, and a second crystal portion serving as a primer for the second target DNA, and a second tag portion having a sequence complementary to the first tag portion.
- PCR comprising: a first additional sequence having a sequence complementary to a nucleotide sequence of at least a part of the nucleotide sequence of the first determinant; And a second additional sequence part having a sequence complementary to a base sequence of at least a part of the base sequence of the first tag part.
- the first determining portion is a forward primer for the first target DNA and the second determining portion is a reverse primer for the first target DNA.
- the first determining portion is a reverse primer for the first target DNA and the second determining portion is a forward primer for the first target DNA.
- the first additional sequence may be selected from the group consisting of Deoxyribonucleic acid (RNA), Ribonucleic acid (RNA), Peptide nucleic acid (PNA), Locked Nucleic Acid (LNA), Bridged nucleic acid (BNA), Hexose nucleic acid nucleic acid, TNA (Threose nucleic acid), CeNA (cyclohexene nucleic acid), or a combination thereof.
- RNA Deoxyribonucleic acid
- RNA Ribonucleic acid
- PNA Peptide nucleic acid
- LNA Locked Nucleic Acid
- BNA Bridged nucleic acid
- Hexose nucleic acid nucleic acid TNA (Threose nucleic acid)
- CeNA cyclohexene nucleic acid
- the second additional sequence may be selected from the group consisting of Deoxyribonucleic acid (RNA), Ribonucleic acid (RNA), Peptide nucleic acid (PNA), Locked Nucleic Acid (LNA), Bridged nucleic acid (BNA), Hexose nucleic acid nucleic acid, TNA (Threose nucleic acid), CeNA (cyclohexene nucleic acid), or a combination thereof.
- RNA Deoxyribonucleic acid
- RNA Ribonucleic acid
- PNA Peptide nucleic acid
- LNA Locked Nucleic Acid
- BNA Bridged nucleic acid
- Hexose nucleic acid nucleic acid TNA (Threose nucleic acid)
- CeNA cyclohexene nucleic acid
- the second nucleic acid complex comprises fluorescent molecules that emit a first light and the first nucleic acid complex comprises a quencher molecule that accepts the first light and emits second light or absorbs the first light,
- a competitive structure may be provided.
- a first light emitted from a tube containing the first nucleic acid complex and the competition structure is irradiated with a first light that is emitted from the first nucleic acid complex and the second nucleic acid after the complementary binding between the first nucleic acid complex and the competitive structure is induced
- the first nucleic acid complex and the second nucleic acid complex are larger than the first light emitted from the tube comprising the first nucleic acid complex and the second nucleic acid complex after inducing complementary binding between the complexes.
- the second additional sequence portion has a base sequence complementary to the base sequence of the first tag portion and the number of bases of the base sequence complementary to the base sequence of the first tag portion
- a competitive structure can be provided that is at least 50% of the number of base pairs complementarily binding between tag portions.
- the number of bases of the base sequence complementary to the base sequence of the first tag portion may be 75% or more of the number of base pairs complementarily binding between the first tag portion and the second tag portion, have.
- the first additional sequence portion has a nucleotide sequence complementary to the nucleotide sequence of the first crystallization portion and the nucleotide sequence complementary to the nucleotide sequence of the first crystallization portion has a nucleotide sequence having an annealing temperature of 10-35 ° C
- a structure may be provided.
- the nucleotide sequence complementary to the nucleotide sequence of the first crystallization part may be provided with a competitive structure wherein the annealing temperature is between 20 and 30 ° C.
- a first nucleic acid complex comprising a first determinant, which is a primer for a first target DNA, and a first tag;
- a second nucleic acid complex comprising a second determinant as a primer for a second target DNA and a second tag having a sequence complementary to the first tag;
- a second additional sequence having a sequence complementary to a nucleotide sequence of at least a part of the nucleotide sequence of the first determinant, and a second additional sequence having a sequence complementary to a nucleotide sequence of at least a part of the nucleotide sequence of the first tag
- a PCR kit may be provided.
- the first determination unit may be a forward primer for the first target DNA
- the second determination unit may be a reverse primer for the first target DNA
- the second determining unit may be a forward primer for the first target DNA, and the first determining unit may be a reverse primer for the first target DNA.
- the first additional sequence may be selected from the group consisting of Deoxyribonucleic acid (RNA), Ribonucleic acid (RNA), Peptide nucleic acid (PNA), Locked Nucleic Acid (LNA), Bridged nucleic acid (BNA), Hexose nucleic acid nucleic acid, TNA (Threose nucleic acid), CeNA (cyclohexene nucleic acid), or a combination thereof.
- RNA Deoxyribonucleic acid
- RNA Ribonucleic acid
- PNA Peptide nucleic acid
- LNA Locked Nucleic Acid
- BNA Bridged nucleic acid
- Hexose nucleic acid nucleic acid TNA (Threose nucleic acid)
- CeNA cyclohexene nucleic acid
- the second additional sequence may be selected from the group consisting of Deoxyribonucleic acid (RNA), Ribonucleic acid (RNA), Peptide nucleic acid (PNA), Locked Nucleic Acid (LNA), Bridged nucleic acid (BNA), Hexose nucleic acid nucleic acid, TNA (Threose nucleic acid), CeNA (cyclohexene nucleic acid), or a combination thereof.
- RNA Deoxyribonucleic acid
- RNA Ribonucleic acid
- PNA Peptide nucleic acid
- LNA Locked Nucleic Acid
- BNA Bridged nucleic acid
- Hexose nucleic acid nucleic acid TNA (Threose nucleic acid)
- CeNA cyclohexene nucleic acid
- the second nucleic acid complex comprises fluorescent molecules that emit a first light and the first nucleic acid complex comprises a quencher molecule that accepts the first light and emits second light or absorbs the first light,
- a competitive structure may be provided.
- the total mass of the at least one competitive construct contained in the PCR kit is a function of the total mass of the at least one first nucleic acid complex contained in the PCR kit and the total mass of the at least one second nucleic acid complex contained in the PCR kit
- a PCR kit that is larger than at least one can be provided.
- the total mass of the at least one competitive construct contained in the PCR kit is a function of the total mass of the at least one first nucleic acid complex contained in the PCR kit and the total mass of the at least one second nucleic acid complex contained in the PCR kit
- a PCR kit can be provided that has a total mass of at least two times as compared to at least one.
- FIG. 1 is a diagram for explaining a nucleic acid complex 1 according to an embodiment of the present application.
- the nucleic acid complex 1 may include a crystal part 100 and a tag part 200.
- the determination unit 100 may include a nucleic acid and / or a nucleic acid analog.
- the determination unit 100 may include a unit molecule of a nucleic acid.
- the determination unit 100 may include a unit molecule of a nucleic acid analogue.
- the determination unit 100 may include a unit molecule of a nucleic acid and a unit molecule of a nucleic acid analog.
- the determination unit 100 may include a unit molecule of a nucleic acid.
- the crystallization unit 100 may include a unit molecule of DNA (Deoxyribonucleic acid), which is an example of a nucleic acid.
- the unit molecule of the DNA may be a substance represented by the following chemical formula (1).
- the base of Formula 1 may be adenine (A), guanine (G), thymine (T) or cytosine (C).
- the base of Formula 1 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the determination unit 100 may include a unit molecule of RNA (Ribonucleic acid), which is an example of a nucleic acid.
- the unit molecule of the RNA may be a substance represented by the following chemical formula (2).
- the base of Formula 2 may be adenine (A), guanine (G), cytosine (C), or uracil (U).
- the base of Formula 2 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the determination unit 100 may include a unit molecule of a nucleic acid.
- the determination unit 100 may be composed of a unit molecule of nucleic acid.
- the determination unit 100 may be composed of a unit molecule of DNA.
- the determination unit 100 may be composed of a unit molecule of RNA.
- the crystallization portion 100 may be composed of a polymer of a unit molecule of a nucleic acid.
- the determination unit 100 may be composed of a polymer of unit molecules of DNA.
- the determination unit 100 may be composed of a polymer of unit molecules of RNA.
- the determination unit 100 may include unit molecules of a first nucleic acid and unit molecules of a second nucleic acid.
- the determination unit 100 may include at least a first nucleic acid and a second nucleic acid.
- the first nucleic acid and the second nucleic acid included in the determination unit 100 may be directly connected.
- the determination unit 100 is provided in such a form that one end of a unit molecule of the first nucleic acid (or a polymer of a unit molecule) and one end of the unit molecule of the second nucleic acid (or a polymer of the unit molecule) are directly connected .
- the first nucleic acid and the second nucleic acid included in the determination unit 100 may be connected to each other through a specific compound.
- the determination unit 100 may be configured such that one end of a unit molecule of a first nucleic acid (or a polymer of a unit molecule) and one end of a unit molecule of a second nucleic acid (or a polymer of a unit molecule) Can be provided.
- the determination unit 100 may be configured such that unit molecules of the first nucleic acid and unit molecules of the second nucleic acid are connected.
- the determination unit 100 may be configured such that unit molecules of DNA and unit molecules of RNA are connected to each other.
- the determination unit 100 may be configured such that a unit molecule of DNA and a unit molecule of DNA are connected to each other through a specific compound (e.g., a crosslinker).
- the determination unit 100 may be configured such that a unit molecule of RNA and a unit molecule of RNA are linked through a specific compound.
- the crystallization unit 100 may be configured such that a polymer of a unit molecule of the first nucleic acid and a unit molecule of the second nucleic acid are connected.
- the determination unit 100 may be configured such that a unit molecule of a DNA unit molecule and a unit molecule of a RNA unit are connected to each other.
- the determination unit 100 may be configured such that a polymer of unit molecules of RNA and unit molecules of DNA are connected.
- the determination unit 100 may be configured such that a unit molecule of DNA and a unit molecule of DNA are connected to each other through a specific compound.
- the determination unit 100 may be configured such that a unit molecule of the RNA unit molecule and a unit molecule of the RNA unit are linked through a specific compound.
- the crystallization unit 100 may be configured such that a polymer of the unit molecule of the first nucleic acid and a polymer of the unit molecule of the second nucleic acid are connected.
- the determination unit 100 may be formed of a polymer of a unit molecule of DNA and a polymer of a unit molecule of RNA.
- the determination unit 100 may be configured such that a polymer of a unit molecule of DNA and a polymer of a unit molecule of DNA are connected through a specific compound.
- the determination unit 100 may be configured such that a polymer of a unit molecule of RNA and a polymer of a unit molecule of RNA are connected through a specific compound.
- the determination unit 100 may include a unit molecule of a nucleic acid analogue.
- the crystallization unit 100 may include a unit molecule of a peptide nucleic acid (PNA), which is an example of a nucleic acid analogue.
- PNA peptide nucleic acid
- the unit molecule of the PNA may be a substance represented by the following chemical formula (3).
- the base of Formula 3 may be adenine (A), guanine (G), thymine (T), cytosine (C), or uracil.
- the base of Formula 3 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the crystallization unit 100 may include a unit molecule of LNA (Locked Nucleic Acid), which is an example of a nucleic acid analog.
- LNA Locked Nucleic Acid
- the unit molecule of the LNA may be a substance represented by the following chemical formula (4).
- the base of Formula 4 may be adenine (A), guanine (G), thymine (T), cytosine (C), or uracil.
- the base of Formula 4 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the crystallization unit 100 may include unit molecules of BNA (Bridged Nucleic Acid), which is an example of a nucleic acid analog.
- BNA Binary Nucleic Acid
- the unit molecule of the BNA may be a substance represented by the following chemical formula (5).
- the base of Formula 5 may be adenine (A), guanine (G), thymine (T), cytosine (C), or uracil.
- the base of Formula 5 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the crystallization unit 100 may include a unit molecule of HNA (Hexose nucleic acid), which is an example of a nucleic acid analog.
- the unit molecule of the HNA may be a substance represented by the following formula (6).
- the base of Formula 6 may be adenine (A), guanine (G), thymine (T), cytosine (C), or uracil.
- the base of Formula 6 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the crystallization unit 100 may include a unit molecule of GNA (Glycol nucleic acid), which is an example of a nucleic acid analogue.
- GNA Glycol nucleic acid
- the unit molecule of GNA may be a substance represented by the following chemical formula (7).
- the base of Formula 7 may be adenine (A), guanine (G), thymine (T), cytosine (C), or uracil.
- the base of Formula 7 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the crystallization unit 100 may include a unit molecule of Threose nucleic acid (TNA), which is an example of a nucleic acid analogue.
- TNA Threose nucleic acid
- the unit molecule of the TNA may be a substance represented by the following chemical formula (8).
- the base of Formula 8 may be adenine (A), guanine (G), thymine (T), cytosine (C), or uracil.
- the base of Formula 8 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the crystallization unit 100 may include a unit molecule of CeNA (cyclohexene nucleic acid), which is an example of a nucleic acid analogue.
- the unit molecule of CeNA may be a substance represented by the following chemical formula (9).
- the base of Formula 9 may be adenine (A), guanine (G), thymine (T), cytosine (C), or uracil.
- the base of Formula 9 may be a purine or pyrimidine derivative such as Hypoxanthine or Xanthine.
- the determination unit 100 may include a unit molecule of a nucleic acid analogue.
- the determination unit 100 may be composed of a unit molecule of a nucleic acid analog.
- the determination unit 100 may be configured as a unit molecule of the LNA.
- the crystallization portion 100 may be composed of a polymer of a unit molecule of a nucleic acid analog.
- the determination unit 100 may be composed of a polymer of unit molecules of PNA.
- the determination unit 100 may include a unit molecule of the first nucleic acid analog and a unit molecule of the second nucleic acid analog.
- the determination unit 100 may include at least a first nucleic acid analog and a second nucleic acid analog.
- the first nucleic acid analogue and the second nucleic acid analogue included in the determination unit 100 may be directly connected.
- the determination unit 100 may be configured such that one end of the unit molecule of the first nucleic acid analog (or the polymer of the unit molecule) and one end of the unit molecule of the second nucleic acid analog (or the polymer of the unit molecule) Can be provided.
- the first nucleic acid analogue and the second nucleic acid analogue included in the determination unit 100 may be connected through a specific compound.
- the determination unit 100 determines that one end of the unit molecule of the first nucleic acid analog (or the polymer of the unit molecule) and one end of the unit molecule of the second nucleic acid analog (or the polymer of the unit molecule) And the like.
- the determination unit 100 may be configured such that unit molecules of the first nucleic acid analogue and unit molecules of the second nucleic acid analogue are connected.
- the determination unit 100 may be configured such that a unit molecule of PNA and a unit molecule of LNA are connected to each other.
- the crystallization unit 100 may be configured such that a unit molecule of the first nucleic acid analog and a unit molecule of the second nucleic acid analogue are connected.
- the determination unit 100 may be configured such that a polymer of a unit molecule of TNA and a unit molecule of GNA are connected to each other.
- the crystallization unit 100 may be configured such that a polymer of a unit molecule of CeNA and a unit molecule of CeNA are linked through a specific compound.
- the crystallization unit 100 may be configured such that a polymer of the unit molecule of the first nucleic acid analogue and a polymer of the unit molecule of the second nucleic acid analogue are connected.
- the crystallization unit 100 may be configured such that a polymer of a unit molecule of BNA and a polymer of a unit molecule of HNA are connected to each other.
- the determination unit 100 may be configured such that the polymer of the unit molecule of the LNA and the polymer of the unit molecule of the LNA are linked through a specific compound.
- the determination unit 100 may include a unit molecule of a nucleic acid and a unit molecule of a nucleic acid analog.
- the determination unit 100 may include at least a first nucleic acid and a first nucleic acid analog.
- the first nucleic acid and the first nucleic acid analog included in the determination unit 100 may be directly connected.
- the determination unit 100 is provided in a form in which one end of a unit molecule of a first nucleic acid (or a polymer of a unit molecule) and one end of a unit molecule of a first nucleic acid analog (or a polymer of a unit molecule) .
- the first nucleic acid and the first nucleic acid analog contained in the crystallization unit 100 may be connected through a specific compound.
- the determination unit 100 determines the type of the first nucleic acid (or the polymer of the unit molecule) and the one of the unit molecule of the first nucleic acid analog (or the polymer of the unit molecule) Lt; / RTI >
- the determination unit 100 may be configured such that unit molecules of a nucleic acid and unit molecules of a nucleic acid analogue are connected.
- the determination unit 100 may be configured such that unit molecules of DNA and unit molecules of LNA are connected to each other.
- the crystallization unit 100 may be configured such that a polymer of a unit molecule of a nucleic acid analogue and a unit molecule of a nucleic acid are connected.
- the determination unit 100 may be configured such that unit molecules of a polymer and RNA of a unit molecule of PNA are connected to each other.
- the crystallization unit 100 may be configured such that a unit molecule of a nucleic acid unit and a unit molecule of a nucleic acid analogue unit are connected.
- the determination unit 100 may be configured such that a polymer of a unit molecule of DNA and a unit molecule of GNA are connected to each other.
- the crystallization unit 100 may be configured such that a polymer of a unit molecule of a nucleic acid and a polymer of a unit molecule of a nucleic acid analogue are connected.
- the determination unit 100 may be configured to connect a polymer of a unit molecule of RNA and a polymer of a unit molecule of CeNA.
- determination unit 100 The materials that can constitute the determination unit 100 and the configuration thereof have been specifically described so far. It should be understood, however, that this is merely a specific embodiment for facilitating understanding of the determination unit 100 according to the present application, and that the determination unit 100 should be construed as limited to including the substances disclosed in this specification It does not mean anything.
- the determination unit 100 can be interpreted to include a unit molecule of a nucleic acid analogue not disclosed in this specification.
- the unit molecule of the nucleic acid analogue may include a base, and at least a part of the constitution other than the base may be chemically modified as compared with the nucleotide.
- the determination unit 100 can be interpreted as including at least one of Chemical Formulas 1 to 9 chemically modified within a range that can be easily changed by a person skilled in the art.
- the determining unit 100 may include deoxycytidine triphosphate (dCTP) in which a cytosine (C) is bonded to the base of Formula 1 and two phosphates are further bound to the phosphoric acid of Formula (1).
- dCTP deoxycytidine triphosphate
- C cytosine
- determination unit 100 operations and examples of the determination unit 100 according to an embodiment of the present application will be specifically described.
- the terminology and function of the determination unit 100 can be more specifically understood based on the material properties of the determination unit 100 and the operation and examples of the determination unit 100 described below will be.
- the determination unit 100 may include a region complementarily binding to a specific base sequence.
- the determination unit 100 may include a region that specifically binds to a specific base sequence.
- the specific nucleotide sequence may be a nucleotide sequence complementary to at least a part of the nucleotide sequence of the crystallization unit 100.
- Means that the determination unit 100 includes a region complementarily binding to a specific nucleotide sequence means that at least one of the electrical, chemical, and physical properties of at least a region of the crystal unit 100 has a specific base sequence Quot; and " associated "
- the determination unit 100 may include a region in which a specific base sequence and a chemical bonding force can occur.
- the determination unit 100 may include a region capable of performing binding of at least one of a covalent bond, a hydrogen bond, an ionic bond, and a hydrophobic bond to a specific base sequence.
- the determination unit 100 may have a unique base sequence.
- the determination unit 100 may have a unique base sequence according to a base type (for example, adenine, guanine, etc.) of a unit molecule of a nucleic acid and / or a unit molecule of a nucleic acid analog contained in the determination unit 100 have.
- a base type for example, adenine, guanine, etc.
- the determination unit 100 can complementarily bind to a specific base sequence.
- the determination unit 100 may specifically bind to a specific base sequence complementary to at least a partial sequence of the unique base sequence of the determination unit 100.
- the determination unit 100 may complementarily bind to a specific base sequence through a hydrogen bond between at least a partial sequence of a unique base sequence of the determination unit 100 and a specific base sequence.
- the determination unit 100 can determine complementary other materials to be coupled.
- the determination unit 100 specifically binds to a specific nucleotide sequence, so that the substance to be bound to the nucleotide sequence of the crystallization unit 100 may include another substance including a specific nucleotide sequence (for example, ssDNA).
- the crystal part 100 may be a single-stranded body containing a nucleic acid and / or a nucleic acid analog.
- the determination unit 100 may be composed of at least one nucleic acid and / or a nucleic acid analogue.
- the determination unit 100 is composed of a plurality of nucleic acids and / or nucleic acid analogs
- the plurality of nucleic acids and / or nucleic acid analogues included in the determination unit 100 may be arranged so that the determination unit 100 forms a single strand. May be connected to each other.
- the determination unit 100 can specifically bind to a nucleic acid including a sequence complementary to the nucleotide sequence of the determination unit 100. At least a part of the nucleotide sequence of the crystallization unit 100 may specifically bind to the nucleotide sequence complementary to the nucleotide sequence of the crystallization unit 100.
- all of the nucleotide sequences of the crystallization unit 100 can be specifically bound to nucleic acids having a sequence complementary to the nucleotide sequence of the crystallization unit 100.
- the determination unit 100 when the determination unit 100 is 5 ⁇ -AAACGGCTCAAATTTT-3 ⁇ , the determination unit 100 can specifically bind to a nucleic acid including 5 ⁇ -AAAAATTTGAGCCGTTT-3 ⁇ .
- the determination unit 100 when the determination unit 100 is 5'-AAACGGCTCAAATTTT-3 ', the determination unit 100 can specifically bind to a nucleic acid including 5'-AAAAATTTGAG-3'.
- the determination unit 100 may include 1 to 100 mer nucleic acid and / or nucleic acid analog.
- the crystallization portion 100 may include 5 to 50mer of nucleic acid and / or nucleic acid analogue.
- the crystallization portion 100 may include 15-30 mer nucleic acid and / or nucleic acid analog.
- the crystal unit 100 includes at least 15-mer or more nucleic acid and / or nucleic acid analogue, the reactivity with the target nucleic acid is higher than that with the case where the crystal unit 100 includes nucleic acid and / Can be improved.
- the determination unit 100 may be a polymerase chain reaction (PCR) primer.
- PCR polymerase chain reaction
- the determination unit 100 can specifically bind to a specific base sequence.
- the specific nucleotide sequence may be a nucleotide sequence complementary to at least a part of the nucleotide sequence of the crystallization unit 100.
- the determination unit 100 is coupled to a target nucleic acid (e.g., a target DNA including a specific base sequence), a nucleotide is connected to the 3 'end of the determination unit 100, 100 can be extended.
- a target nucleic acid e.g., a target DNA including a specific base sequence
- the target nucleic acid to which the determination unit 100 is coupled is linked to a nucleotide (for example, dNTP or ddNTP) at the 3 'end of the determination unit 100 by a polymerase as the PCR proceeds,
- the 3'-end side of the crystal section 100 can be extended.
- the determination unit 100 when the determination unit 100 is 5'-AAACGGCTCAAATTTT-3 ⁇ , the determination unit 100 can specifically bind to a target nucleic acid containing 5'-AAAAATTTGAGCCGTTT-3 ' A unit molecule (e.g., a nucleotide) of a nucleic acid having a base sequence complementary to the base in the region adjacent to the 5'-side of the target nucleic acid is connected to the 3 ' end of the determination unit 100, End side can be extended.
- a unit molecule e.g., a nucleotide
- the form in which the nucleotide is connected to the 3 'end of the determination unit 100 may be a covalent bond.
- the crystal unit 100 is composed of a polymer of unit molecules of DNA
- a nucleotide can be connected to the 3 'terminal of the crystal unit 100 in a form in which OH in the phosphate group reacts to form a covalent bond.
- the determination unit 100 may include 1 to 50 mer nucleic acid and / or nucleic acid analog.
- the crystallization portion 100 may include a 5 to 30-mer nucleic acid and / or a nucleic acid analog.
- the crystallization portion 100 may include a 10-25mer nucleic acid and / or a nucleic acid analog.
- the determination unit 100 determines whether or not the determination unit 100 includes nucleic acid and / And the target nucleic acid can be improved.
- the determination unit 100 may include at least two nucleic acids, and the first nucleic acid and the second nucleic acid may be connected through a specific compound.
- the determination unit 100 includes at least two unit nucleic acid molecules, and the first nucleic acid (the unit molecule of the nucleic acid or the polymer of the unit molecule of the nucleic acid) and the second nucleic acid (the unit molecule of the nucleic acid or the polymer of the unit molecule of the nucleic acid ) Can be configured to be linked through a particular compound.
- the determination unit 100 may be configured such that a first strand composed of a polymer of a unit molecule of DNA and a second strand composed of a polymer of a unit molecule of DNA are connected through a specific compound.
- the first and second strands may be connected to each other through a polydeoxyinosine linker.
- the first strand and the second strand which is relatively shorter than the first strand, may be provided through the polydeoxyinosine linker.
- the tag unit 200 may include a compound including at least one of F, N, O, and H to enable hydrogen bonding.
- the tag unit 200 may be a polymer produced by polymerizing a monomer containing at least one of F, N, O,
- the tag unit 200 may be composed of a polymer of a unit molecule represented by the following formula (10).
- the tag unit 200 may be formed by polymerizing a monomer comprising at least one of F, N, O, and H, and a first polymer produced by polymerizing a monomer containing at least one of F, N, And the resulting second polymer is linked through a specific compound.
- the tag unit 200 may be formed by polymerizing a monomer containing at least one of F, N, O, and H, and a polymer and any compound connected thereto.
- the tag unit 200 may include a nucleic acid and / or a nucleic acid analog.
- the tag unit 200 may include a unit molecule of a nucleic acid.
- the tag unit 200 may include a unit molecule of a nucleic acid analogue.
- the tag unit 200 may include a unit molecule of a nucleic acid and a unit molecule of a nucleic acid analogue.
- the tag unit 200 may include a unit molecule of a nucleic acid.
- the tag unit 200 may include a unit molecule of DNA (Deoxyribonucleic acid), which is an example of a nucleic acid.
- the unit molecule of the DNA may be a substance represented by the chemical formula (1).
- the tag unit 200 may include a unit molecule of RNA (Ribonucleic acid), which is an example of nucleic acid.
- the unit molecule of the RNA may be a substance represented by the above formula (2).
- the tag unit 200 may include a unit molecule of nucleic acid.
- the tag unit 200 may be composed of a unit molecule of nucleic acid.
- the tag unit 200 may be composed of DNA unit molecules.
- the tag unit 200 may be composed of unit molecules of RNA.
- the tag unit 200 may be composed of a polymer of a unit molecule of nucleic acid.
- the tag unit 200 may be composed of a polymer of unit molecules of DNA.
- the tag unit 200 may be composed of a polymer of unit molecules of RNA.
- the tag unit 200 may include a unit molecule of a first nucleic acid and a unit molecule of a second nucleic acid.
- the tag unit 200 may include at least a first nucleic acid and a second nucleic acid.
- the first nucleic acid and the second nucleic acid included in the tag unit 200 may be directly connected.
- the tag unit 200 is provided in such a form that one end of a unit molecule of a first nucleic acid (or a polymer of a unit molecule) and one end of a unit molecule of a second nucleic acid (or a polymer of a unit molecule) are directly connected .
- the first nucleic acid and the second nucleic acid included in the tag unit 200 may be connected through a specific compound.
- the tag unit 200 has a structure in which one end of a unit molecule of a first nucleic acid (or a polymer of a unit molecule) and one end of a unit molecule of a second nucleic acid (or a polymer of a unit molecule) Can be provided.
- the tag unit 200 may be configured such that unit molecules of a first nucleic acid and unit molecules of a second nucleic acid are connected.
- the tag unit 200 may be configured such that unit molecules of DNA and unit molecules of RNA are connected.
- the tag unit 200 may be configured such that a unit molecule of DNA and a unit molecule of DNA are connected through a specific compound.
- the tag unit 200 may be configured such that a unit molecule of RNA and a unit molecule of RNA are linked through a specific compound.
- the tag unit 200 may be configured such that a polymer of a unit molecule of the first nucleic acid and a unit molecule of the second nucleic acid are connected.
- the tag unit 200 may be configured such that a unit molecule of DNA and a unit molecule of RNA are connected.
- the tag unit 200 may be configured such that a polymer of unit molecules of RNA and unit molecules of DNA are connected.
- the tag unit 200 may be configured such that a unit molecule of DNA and a unit molecule of DNA are connected to each other through a specific compound.
- the tag unit 200 may be configured in such a manner that a unit molecule of a unit molecule of RNA and a unit molecule of RNA are linked through a specific compound.
- the tag unit 200 may be configured such that a polymer of a unit molecule of a first nucleic acid and a polymer of a unit molecule of a second nucleic acid are connected.
- the tag unit 200 may include a polymer of a unit molecule of DNA and a polymer of unit molecule of RNA.
- the tag unit 200 may be configured such that a polymer of a unit molecule of DNA and a polymer of a unit molecule of DNA are connected through a specific compound.
- the tag unit 200 may be configured such that a polymer of a unit molecule of RNA and a polymer of a unit molecule of RNA are connected through a specific compound.
- the tag unit 200 may include a unit molecule of a nucleic acid analogue.
- the tag unit 200 may include a unit molecule of PNA (peptide nucleic acid), which is an example of a nucleic acid analogue.
- the unit molecule of the PNA may be a substance represented by the above formula (3).
- the tag unit 200 may include a unit molecule of LNA (Locked Nucleic Acid), which is an example of a nucleic acid analogue.
- LNA Locked Nucleic Acid
- the unit molecule of the LNA may be a substance represented by the following chemical formula (4).
- the tag unit 200 may include a unit molecule of BNA (Bridged Nucleic Acid), which is an example of a nucleic acid analogue.
- BNA Binary Nucleic Acid
- the unit molecule of the BNA may be a substance represented by the above formula (5).
- the tag unit 200 may include a unit molecule of HNA (Hexose nucleic acid), which is an example of a nucleic acid analogue.
- the unit molecule of the HNA may be a substance represented by the above formula (6).
- the tag unit 200 may include a unit molecule of GNA (Glycol nucleic acid), which is an example of a nucleic acid analogue.
- GNA Glycol nucleic acid
- the unit molecule of the GNA may be a substance represented by the above formula (7).
- the tag unit 200 may include a unit molecule of Threose nucleic acid (TNA), which is an example of a nucleic acid analogue.
- TNA Threose nucleic acid
- the unit molecule of the TNA may be a substance represented by the following formula (8).
- the tag unit 200 may include a unit molecule of CeNA (cyclohexene nucleic acid), which is an example of a nucleic acid analogue.
- the unit molecule of the CeNA may be a substance represented by the above formula (9).
- the tag unit 200 may include a unit molecule of a nucleic acid analogue.
- the tag unit 200 may be composed of a unit molecule of a nucleic acid analogue.
- the tag unit 200 may be composed of a unit molecule of the LNA.
- the tag unit 200 may be composed of a polymer of unit molecules of a nucleic acid analog.
- the tag unit 200 may be composed of a polymer of unit molecules of PNA.
- the tag unit 200 may include a unit molecule of the first nucleic acid analogue and a unit molecule of the second nucleic acid analogue.
- the tag unit 200 may include at least a first nucleic acid analog and a second nucleic acid analog.
- the first nucleic acid analogue and the second nucleic acid analogue included in the tag unit 200 may be directly connected.
- the tag unit 200 has a structure in which one end of the unit molecule of the first nucleic acid analog (or the polymer of the unit molecule) and one end of the unit molecule of the second nucleic acid analog (or the polymer of the unit molecule) Can be provided.
- the first nucleic acid analogue and the second nucleic acid analogue included in the tag unit 200 may be connected through a specific compound.
- one end of the unit molecule of the first nucleic acid analog (or the polymer of the unit molecule) and one end of the unit molecule of the second nucleic acid analog (or the polymer of the unit molecule) And the like.
- the tag unit 200 may be configured such that unit molecules of the first nucleic acid analogue and unit molecules of the second nucleic acid analogue are connected.
- the tag unit 200 may be configured such that a unit molecule of a PNA and a unit molecule of an LNA are connected to each other.
- the tag unit 200 may be configured such that a unit molecule of the first nucleic acid analog and a unit molecule of the second nucleic acid analogue are connected.
- the tag unit 200 may be configured such that a polymer of a unit molecule of TNA and a unit molecule of GNA are connected to each other.
- the tag unit 200 may be configured such that a polymer of a unit molecule of CeNA and a unit molecule of CeNA are connected through a specific compound.
- the tag unit 200 may be configured such that a polymer of the unit molecule of the first nucleic acid analogue and a polymer of the unit molecule of the second nucleic acid analogue are connected.
- the tag unit 200 may be configured such that a polymer of a unit molecule of BNA and a polymer of a unit molecule of HNA are connected.
- the tag unit 200 may be configured such that the polymer of the unit molecule of the LNA and the polymer of the unit molecule of the LNA are connected through a specific compound.
- the tag unit 200 may include a unit molecule of a nucleic acid and a unit molecule of a nucleic acid analog.
- the tag unit 200 may include at least a first nucleic acid and a first nucleic acid analog.
- the first nucleic acid and the first nucleic acid analog contained in the tag unit 200 may be directly connected.
- the tag unit 200 is provided in a form in which one end of a unit molecule of a first nucleic acid (or a polymer of a unit molecule) and a unit molecule of a first nucleic acid analog (or a polymer of a unit molecule) are directly connected .
- the first nucleic acid and the first nucleic acid analog contained in the tag unit 200 may be connected through a specific compound.
- the tag unit 200 has a structure in which one end of a unit molecule of a first nucleic acid (or a polymer of a unit molecule) and one end of a unit molecule of a first nucleic acid analog (or a polymer of a unit molecule) Lt; / RTI >
- the tag unit 200 may be configured such that unit molecules of a nucleic acid and unit molecules of a nucleic acid analogue are connected.
- the tag unit 200 may be configured such that DNA unit molecules and LNA unit molecules are connected.
- the tag unit 200 may be configured such that a unit molecule of a nucleic acid analog unit and a unit molecule of a nucleic acid are connected.
- the tag unit 200 may be configured such that unit molecules of a polymer and RNA of a unit molecule of PNA are connected.
- the tag unit 200 may be configured such that a unit molecule of a nucleic acid unit and a unit molecule of a nucleic acid analogue unit are connected.
- the tag unit 200 may be configured such that a polymer of a unit molecule of DNA and a unit molecule of GNA are connected to each other.
- the tag unit 200 may be configured such that a polymer of a unit molecule of a nucleic acid and a polymer of a unit molecule of a nucleic acid analogue are connected.
- the tag unit 200 may include a polymer of a unit molecule of RNA and a polymer of unit molecules of CeNA.
- tag unit 200 The materials and constitution of the tag unit 200 have been specifically described so far. It is to be understood that this is only a specific embodiment for facilitating understanding of the tag unit 200 according to the present application, and should be construed to be limited to the case where the tag unit 200 includes the substance disclosed in this specification It does not mean anything.
- the tag unit 200 can be interpreted to include a compound not disclosed herein.
- the tag unit 200 can be interpreted to include a unit molecule of the nucleic acid analogue not disclosed in this specification.
- the unit molecule of the nucleic acid analogue may include a base, and at least a part of the constitution other than the base may be chemically modified as compared with the nucleotide.
- the tag unit 200 can be interpreted as including at least one of Chemical Formulas 1 to 10 chemically modified within a range that is easily changed by a person skilled in the art.
- the tag unit 200 may include thymidine phosphoric acid (TDP) in which thymidine (T) is bound to the base of Formula 2 and phosphoric acid of Formula 2 is further coupled to one phosphoric acid.
- TDP thymidine phosphoric acid
- tag unit 200 operations and examples of the tag unit 200 according to an embodiment of the present application will be specifically described.
- the terminology and function of the tag unit 200 can be more specifically understood based on the material properties of the tag unit 200 and the operation and examples of the tag unit 200 described below will be.
- the tag unit 200 may include a region complementary to a specific base sequence.
- the tag unit 200 may include a region that specifically binds to a specific base sequence.
- the specific nucleotide sequence may be a nucleotide sequence complementary to at least a part of the nucleotide sequence of the tag unit 200.
- the tag unit 200 includes a region complementarily binding to a specific nucleotide sequence means that at least one of the electrical, chemical, and physical properties of at least a part of the region of the tag unit 200 has a specific nucleotide sequence Quot; and " associated "
- the tag unit 200 may include a region in which a specific base sequence and a chemical binding force can occur.
- the tag unit 200 may include a region capable of performing at least one binding of a specific base sequence with a covalent bond, a hydrogen bond, an ionic bond, or a hydrophobic bond.
- the tag unit 200 may include a region complementary to the nucleic acid complex 1.
- the tag unit 200 may include an area complementary to the tag unit 200 of the nucleic acid complex 1.
- the compound included in the tag unit 200 may have a unique chemical structure.
- the tag unit 200 has a unique chemical structure depending on the distance between the element and the element of the compound included in the tag unit 200 and the kind of the element included in the tag unit 200 .
- the tag unit 200 may be complementarily coupled to the tag unit 200 of the other nucleic acid complex 1 having a specific chemical structure.
- the tag unit 200 can be complementarily combined with the tag unit 200 of the other nucleic acid complex 1 by hydrogen bonding with a specific chemical structure corresponding to the unique chemical structure of the tag unit 200 .
- the hydrogen of the tag unit 200 and the nucleic acid complex 1 may be hydrogen bonded to the nitrogen of the tag unit 200.
- the tag unit 200 when the tag unit 200 includes a unit molecule of a nucleic acid and / or a nucleic acid analogue, the tag unit 200 may have a unique base sequence.
- the tag unit 200 may have a unique nucleotide sequence according to a base type (for example, adenine, guanine, etc.) of a unit molecule of a nucleic acid and / or a unit molecule of a nucleic acid analog contained in the tag unit 200 have.
- a base type for example, adenine, guanine, etc.
- the tag unit 200 may be complementarily coupled to the tag unit 200 of the other nucleic acid complex 1 including a specific base sequence.
- the tag unit 200 is hydrogen-bonded to a specific nucleotide sequence corresponding to at least a part of the unique nucleotide sequence of the tag unit 200 so as to be complementary to the tag unit 200 of the nucleic acid complex 1 Can be combined.
- the tag unit 200 and the tag unit 200 of the nucleic acid complex 1 have a polymer of a unit molecule of DNA
- the adenine (A) in the nucleotide sequence of the tag unit (200) can be hydrogen bonded to guanine (G) in the nucleotide sequence of the tag unit (200) of the nucleic acid complex (1) (T) in the nucleotide sequence of SEQ ID NO: 200.
- the tag portion 200 may be a single-stranded body including a nucleic acid and / or a nucleic acid analog.
- the tag unit 200 may be composed of at least one nucleic acid and / or a nucleic acid analogue.
- the tag unit 200 is composed of a plurality of nucleic acids and / or nucleic acid analogs
- the plurality of nucleic acids and / or nucleic acid analogues included in the tag unit 200 may be a single strand, May be connected to each other.
- the tag unit 200 can specifically bind to the tag unit 200 of the nucleic acid complex 1 including a sequence complementary to the nucleotide sequence of the tag unit 200 have. At least a part of the nucleotide sequence of the tag unit 200 may specifically bind to the tag unit 200 of the nucleic acid complex 1.
- all of the nucleotide sequences of the tag unit 200 can be specifically bound to the tag unit 200 of the nucleic acid complex 1.
- the tag unit 200 may include the tag unit 200 of the other nucleic acid complex 1 including TTTTTTTTTT (SEQ ID NO: 7) Specific binding.
- some of the nucleotide sequences of the tag unit 200 may specifically bind to the tag unit 200 of the nucleic acid complex 1.
- the tag unit 200 may include a tag unit 200 of the other nucleic acid complex 1 including TTTTTTTT (SEQ ID NO: 3) Specific binding. At least two bases (i.e., AA) of the tag unit 200 may not participate in the binding.
- nucleic acid complex 1 The operation of the nucleic acid complex 1 according to one embodiment of the present application will be specifically described in the following table of contents 2.2 tag part 200 and 2.4 nucleic acid complex pair 10 according to the seventh embodiment do.
- the tag unit 200 may include 1 to 50-mer nucleic acid and / or nucleic acid analogue.
- the tag unit 200 may include 3- to 25-mer nucleic acids and / or nucleic acid analogs.
- the tag unit 200 may include a 5 to 20-mer nucleic acid and / or a nucleic acid complex (1).
- the tag unit 200 may be a probe for PCR clamping.
- the tag unit 200 may be a single-stranded product containing a nucleic acid and / or a nucleic acid analogue in which at least one base sequence is different from the primer used for PCR.
- the tag unit 200 may be configured to be different from the base sequence of the determination unit 100 by at least one base sequence.
- the tag unit 200 can specifically bind to a nucleic acid having a sequence similar to a specific base sequence to which the determination unit 100 binds.
- the tag unit 200 may be configured such that the determination unit 100 determines whether or not the target base sequence of the determination unit 100 (that is, at least a part of the base sequence of the determination unit 100) To a similar sequence similar to that of the nucleotide sequence of SEQ ID NO: 1).
- the tag unit 200 may specifically bind to a similar sequence similar to the target sequence of the determination unit 100 to prevent the determination unit 100 from being mismatched and mated with the similar sequence.
- the determination unit 100 specifically binds the target base sequence
- the tag unit 200 can specifically bind 5'-CTTGCGGTAG-3 ⁇ of 3'-ATGCTTGCGGTAG-3 ⁇ which is similar to the target sequence.
- the tag unit 200 can prevent the determination unit 100 from being mismatched and coupled with the similar sequence to the determination unit 100.
- the tag unit 200 may include 1 to 50-mer nucleic acid and / or nucleic acid analogue.
- the tag unit 200 may include a 5 to 30-mer nucleic acid and / or a nucleic acid analog.
- the tag unit 200 may include 10-25mer nucleic acids and / or nucleic acid analogs.
- the tag unit 200 may include a nucleic acid and / And the similar sequence can be improved.
- the materials, operations, and examples of the respective components i.e., the crystal unit 100 and the tag unit 200.
- FIG. 2 is a diagram for explaining the positional relationship among the components of the nucleic acid complex 1 according to one embodiment of the present application.
- the nucleic acid complex 1 may include a crystal portion 100 and a tag portion 200.
- the crystal unit 100 and the tag unit 200 of the nucleic acid complex 1 may have a predetermined positional relationship.
- the determination unit 100 and the tag unit 200 may be connected. In other words, one end of the determination unit 100 and one end of the tag unit 200 can be directly connected.
- One end of the determination unit 100 and one end of the tag unit 200 may be connected based on a chemical bonding force.
- One end of the determination unit 100 and one end of the tag unit 200 may be connected based on at least one of a covalent bond, a hydrogen bond, an ionic bond, and a hydrophobic bond.
- the determination unit 100 and the tag unit 200 may be connected by a covalent bond.
- the determination unit 100 and the tag unit 200 may be connected in such a manner that a 3 'end of the tag unit 200 and a 5' end of the determination unit 100 are directly connected to each other (See Fig. 2 (a)).
- the determination unit 100 and the tag unit 200 are made of a polymer of a unit molecule of DNA
- the H group of the 3'end of the tag unit 200 and the H group of the 5'end of the crystal unit 100 OH may react and covalently bond to each other, and the crystal unit 100 and the tag unit 200 may be connected to each other.
- the determination unit 100 and the tag unit 200 may be connected to each other in such a manner that the 5'end of the tag unit 200 and the 3'end of the determination unit 100 are directly connected to each other (See Fig. 2 (b)).
- the crystal unit 100 and the tag unit 200 are made of a polymer of a unit molecule of DNA
- the H group of the 3'end of the crystal unit 100 and the H group of the 5'end of the tag unit 200 OH may react and covalently bond to each other, and the crystal unit 100 and the tag unit 200 may be connected to each other.
- the determination unit 100 and the tag unit 200 may be connected through a separate material.
- one end of the determination unit 100 and one end of the tag unit 200 may be connected through a specific compound. Concrete examples related to this will be described in detail in the following Table of Contents in relation to each component of the nucleic acid complex (1).
- nucleic acid complex 1 according to one embodiment of the present application has been described.
- the nucleic acid complex 1 according to the first embodiment described below is the same except that it further includes the label portion 300 in comparison with the nucleic acid complex 1 described above. Therefore, in describing the first embodiment, the same reference numerals are assigned to the components common to the above-described embodiment, and detailed description thereof is omitted.
- 3 is a view for explaining the nucleic acid complex 1 according to the first embodiment of the present application.
- the nucleic acid complex 1 according to the first embodiment of the present application may include a crystal part 100, a tag part 200, and a label part 300.
- the label portion 300 may include small objects having physical properties (e.g., size) and chemical properties (e.g., changes in chemical structure).
- the label portion 300 may be a metal nanoparticle.
- the label portion 300 may be a particle comprising a transition metal, a post-transition metal, and / or a metalloid, and having a particle size of several to several hundred nanometers (about 10-9 m).
- the label portion 300 may be magnetic nanoparticles.
- the label portion 300 may be formed of a material that is capable of absorbing electromagnetic radiation (such as iron oxide (Fe2O3, Fe3O4), ferrite (a form in which one Fe atom of Fe3O4 is replaced with another magnetic related atom, ex: CoFe2O4, MnFe2O4) (E.g., FePt, CoPt, etc.), and the like, and the size of the particles may be several to several hundred nanometers (about 10-9 m).
- electromagnetic radiation such as iron oxide (Fe2O3, Fe3O4), ferrite (a form in which one Fe atom of Fe3O4 is replaced with another magnetic related atom, ex: CoFe2O4, MnFe2O4) (E.g., FePt, CoPt, etc.), and the like
- the size of the particles may be several to several hundred nanometers (about 10-9 m).
- the label portion 300 may be a latex bead.
- the label portion 300 comprises an amorphous polymer (e.g., polystyrene) and may be spherical polymer particles in the colloidal size range.
- amorphous polymer e.g., polystyrene
- the label portion 300 may include particles that donate energy.
- the label portion 300 may include particles that receive energy.
- the label portion 300 may include particles for donating and receiving energy.
- the energy donated or received in the label portion 300 may include at least one of chemical energy, electrical energy, luminescent energy, and magnetic field energy.
- the label portion 300 may include particles that donate energy.
- the label portion 300 may be a particle for donating electron energy.
- the label portion 300 may be an oxide that loses electrons.
- the label portion 300 may be a particle that donates fluorescence resonance energy.
- the label portion 300 may be a luminescent material.
- the label unit 300 may be a fluorescent molecule that emits light of a specific wavelength when light is projected.
- the labeling unit 300 may include a labeling unit such as FAM, JOE, TET, HEX, VIC, Oregon Green®, TAMRA, ROX, Cyanine-3, Cyanine-3.5, Cyanine- Or Cyan Fluorescent Protein (CFP).
- the label portion 300 may include particles that receive energy.
- the label portion 300 may be a particle that provides electron energy.
- the label portion 300 may be a reducing material for obtaining electrons.
- the label portion 300 may be particles that accept fluorescence resonance energy.
- the label portion 300 may be a light-emitting material.
- the label unit 300 may be a black hole quencher (BHQ).
- BHQ black hole quencher
- the black hole quencher may be any one of formulas (11) to (14) below.
- the label portion 300 may be a fluorescent conversion material.
- the label portion 300 may be a green fluorescence protein (GFP) that receives energy from Aequorin and emits green fluorescence of 508 nm.
- GFP green fluorescence protein
- YFP yellow fluorescent protein
- CFP Cyan Fluorescent Protein
- the label portion 300 may be involved in labeling the nucleic acid complex 1.
- the label portion 300 may function as a mark for confirming information on the nucleic acid complex 1.
- the label unit 300 can identify the nucleic acid complex 1 by identifying information on the nucleic acid complex 1 including the label unit 300 according to the characteristics of the label unit 300.
- information on the nucleic acid complex 1 can be detected based on information (for example, particle size, mobility, position, etc.) of the particles of the label portion 300 have.
- the label unit 300 is a particle having physical properties
- the presence or absence of the nucleic acid complex 1 may be confirmed depending on whether the label unit 300 is detected.
- the degree of coagulation of the nucleic acid complex 1 may be determined according to the position of the label portion 300.
- information on movement and movement of the nucleic acid complex 1 for example, speed ) And the like.
- the nucleic acid complex 1 including the label portion 300 in a form of detecting at least one of chemical, electrical, optical, and magnetic signals generated from the label portion 300 Information can be detected.
- the label portion 300 is a substance that emits energy
- the presence or absence of the nucleic acid complex 1 and / or the distribution of the nucleic acid complex 1 and the like based on the energy (that is, the signal) Can be confirmed.
- At least one of the chemical, electrical, optical, and magnetic signals involved in the label portion 300 is detected, and the nucleic acid complex 1 including the label portion 300 Information can be detected.
- the label portion 300 is a material that receives energy and releases energy or absorbs energy other than the received energy, the characteristic of the label portion 300 detected in a specific environmental condition The information of the nucleic acid complex 1 can be confirmed.
- the label portion 300 may be gold nanoparticles.
- the label portion 300 may include gold and particles having a size of several to several hundred nanometers.
- the label portion 300 may be formed in a form of detecting information (for example, particle size, mobility, position, etc.) of particles of the label portion 300 Nucleic acid complex (1) may be labeled.
- detecting information for example, particle size, mobility, position, etc.
- the presence or absence of the label unit 300 can be confirmed depending on whether particles corresponding to the size of the label unit 300 are detected through an optical sensor or the like.
- the presence or absence of the nucleic acid complex 1 can be confirmed depending on whether or not the label portion 300 is detected.
- the degree of coagulation of the label portion 300 can be confirmed.
- the degree of coagulation of the nucleic acid complex 1 can be confirmed.
- the information (e.g., speed) about the movement and movement of the nucleic acid complex 1 can be confirmed according to the progress of the movement of the label portion 300.
- the nucleic acid complex 1 including the label portion 300 may be labeled in such a manner as to detect information on the reactivity of the particles of the label portion 300.
- the intensity of the particles of the label unit 300 can be confirmed.
- the presence or absence of the nucleic acid complex 1 can be confirmed depending on whether or not the label portion 300 is detected.
- the distribution of the label portion 300 can be confirmed by a method of analyzing the current detected according to the application of the voltage to the label portion 300 (e.g., cyclic voltammetry). Depending on the distribution of the label portion 300, the distribution of the nucleic acid complex 1 can be confirmed.
- the label portion 300 may be a fluorescent material.
- the label unit 300 may be a fluorescent molecule that emits light of a specific wavelength when light is projected.
- the nucleic acid complex 1 including the label portion 300 may be configured to detect at least one of chemical, electrical, optical, and magnetic signals generated from the label portion 300, Can be detected.
- the presence or absence of particles in the label portion 300 can be confirmed by detecting an optical signal generated from the label portion 300.
- the presence or absence of the label unit 300 can be confirmed by detecting a signal in a specific wavelength band generated from the label unit 300.
- the presence or absence of particles in the label unit 300 can be confirmed by detecting whether a signal in a specific wavelength band generated from the label unit 300 exceeds a threshold value.
- the presence or absence of the nucleic acid complex 1 can be confirmed depending on whether or not the label portion 300 is detected.
- the distribution of the label can be confirmed by detecting an optical signal generated from the label portion 300.
- the distribution of the nucleic acid complex 1 can be confirmed according to the distribution of the label portion 300.
- the label portion 300 may be a quencher material.
- the label unit 300 may be a quantizer that converts or emits energy of a specific wavelength band that is projected when energy of a specific wavelength band is projected.
- At least one of the chemical, electrical, optical, and magnetic signals involved in the label portion 300 is detected, and the information of the nucleic acid complex 1 including the label portion 300 Can be detected.
- the presence or absence of the label unit 300 can be confirmed by checking whether or not the detected optical signal is affected by the label unit 300.
- the label portion 300 is formed after a specific environmental condition is established as compared with an optical signal generated from the label portion 300 before a specific environmental condition is applied (for example, a nucleic acid complex 1 is introduced)
- the label portion 300 can be labeled based on whether or not the optical signal is changed and / or changed. According to the label of the label unit 300, the nucleic acid complex 1 including the label unit 300 may be labeled.
- nucleic acid complex 1 including the determination unit 100, the tag unit 200 and the label unit 300, the respective components (i.e., the determination unit 100, the tag unit 200, (300)) have been described in detail.
- FIG. 4 is a diagram for explaining the positional relationship among the components of the nucleic acid complex 1 according to one embodiment of the present application.
- the nucleic acid complex 1 may include a crystal part 100, a tag part 200, and a label part 300.
- the crystal unit 100, the tag unit 200, and the label unit 300 of the nucleic acid complex 1 may have a predetermined positional relationship.
- the determination unit 100, the tag unit 200, and the label unit 300 may be connected.
- the determination unit 100, the tag unit 200, and the label unit 300 may be connected based on a chemical bonding force.
- the determination unit 100, the tag unit 200, and the label unit 300 may be connected based on at least one of a covalent bond, a hydrogen bond, an ionic bond, and a hydrophobic bond.
- the tag unit 200 can be positioned between the determination unit 100 and the label unit 300 (see FIG. 4 (a)).
- the determination unit 100 may be connected to one end of the tag unit 200.
- One end of the determination unit 100 may be connected to one end of the tag unit 200 by chemical coupling.
- One end of the tag unit 200 and one end of the determination unit 100 may be directly connected.
- one end of the tag unit 200 and one end of the determination unit 100 may be connected through a specific compound.
- the label unit 300 may be connected to the other end of the tag unit 200 (i.e., the other end of the tag unit 200). One end of the label unit 300 may be connected to the other end of the tag unit 200 by chemical bonding. The other end of the tag unit 200 and one end of the label unit 300 may be directly connected. Alternatively, the other end of the tag unit 200 and one end of the label unit 300 may be connected through a specific compound.
- the nucleic acid complex 1 further includes a label portion 300, and the label portion 300 and the crystal portion
- the tag unit 200 is connected between the tag unit 100 and the tag unit 200.
- the label unit 300 may be positioned between the determination unit 100 and the tag unit 200 (see FIG. 4 (b)).
- the determination unit 100 may be connected to one end of the label unit 300.
- One end of the crystallization part 100 may be connected to one end of the label part 300 by chemical bonding.
- One end of the label unit 300 and one end of the determination unit 100 may be directly connected.
- one end of the label portion 300 and one end of the determination portion 100 may be connected through a specific compound.
- the tag unit 200 may be connected to the other end of the label unit 300 (that is, the other end of the label unit 300). One end of the tag unit 200 may be connected to the other end of the label unit 300 by chemical bonding. The other end of the label unit 300 and one end of the tag unit 200 may be directly connected. The other end of the label portion 300 and one end of the tag portion 200 may be connected to each other through a specific compound.
- the nucleic acid complex 1 according to the present invention further includes a label portion 300, and the determination portion 100 and the tag portion And the label portion (300) is connected between the label portion (200).
- the determination unit 100 may be positioned between the tag unit 200 and the label unit 300 (see FIG. 4 (c)).
- the tag unit 200 may be connected to one end of the determination unit 100.
- One end of the tag unit 200 may be connected to one end of the determination unit 100 according to a chemical coupling.
- One end of the determination unit 100 and one end of the tag unit 200 may be directly connected.
- one end of the determination unit 100 and one end of the tag unit 200 may be connected through a specific compound.
- the label unit 300 may be connected to the other end of the determination unit 100 (i.e., the other end of the determination unit 100). One end of the label unit 300 may be connected to the other end of the determination unit 100 by chemical bonding. The other end of the determination unit 100 and one end of the label unit 300 may be directly connected. The other end of the determination unit 100 and one end of the label unit 300 may be connected through a specific compound.
- the nucleic acid complex 1 according to the present invention further includes a label portion 300, and the label portion 200 and the label portion 300 (100) is connected between the nucleic acid complex (300) and the nucleic acid complex (1).
- nucleic acid complex 1 according to the first embodiment of the present application has been described.
- the nucleic acid complex 1 according to the second embodiment described below does not include the label portion 300 as compared with the nucleic acid complex 1 according to the first embodiment and further includes a connecting portion 400 The same is true. Therefore, in describing the second embodiment, the same reference numerals are assigned to the same components as those of the above-described embodiment, and a detailed description thereof is omitted.
- 5 is a diagram for explaining the nucleic acid complex 1 according to the second embodiment of the present application.
- the nucleic acid complex 1 may include a crystal part 100, a tag part 200, and a connection part 400. As shown in FIG.
- connection portion 400 may be a compound including at least one of H, O, F, N, S, C
- the connection unit 400 may include a compound having a predetermined length and including at least one of H, O, F, N, S, C,
- connection 400 may comprise carbon comprising at least one single bond.
- the connecting portion 400 may include a compound of Formula 15 below.
- the connection 400 may be hexaethyleneglycol.
- connection portion 400 may include carbon having a resonance structure.
- connection portion 400 may include carbon including at least one double bond.
- connection unit 400 may include an abasic Furan.
- the linkage 400 may comprise a compound of Formula 16 below.
- connection portion 400 may include a nucleic acid analog and / or a modified nucleic acid.
- the connection unit 400 may include a unit molecule of the modified nucleic acid.
- the connection unit 400 may include a unit molecule of a nucleic acid analogue.
- the connection unit 400 may include a unit molecule of the modified nucleic acid and a unit molecule of the nucleic acid analog.
- connection unit 400 may include a unit molecule of the modified nucleic acid.
- the unit molecule of the modified nucleic acid may be a molecule in which at least a part of the structure of the base in the unit molecule of DNA (Deoxyribonucleic acid), which is an example of nucleic acid, is modified.
- the unit molecule of the modified nucleic acid may be a molecule in which at least a part of the structure of the base in the unit molecule of RNA (Ribonucleic acid), which is an example of nucleic acid, is modified.
- connection unit 400 may include a unit molecule of the modified nucleic acid.
- connection unit 400 may include a unit molecule of the modified nucleic acid.
- connection unit 400 may include a unit molecule of RNA in which some of the bases are modified.
- connection portion 400 may be composed of a polymer of the unit molecule of the modified nucleic acid.
- connection unit 400 may be composed of a polymer of a unit molecule of DNA in which the entire base is modified.
- connection unit 400 may include a unit molecule of the first modified nucleic acid and a unit molecule of the second modified nucleic acid.
- the connection portion 400 may include at least a first modified nucleic acid and a second modified nucleic acid.
- connection unit 400 may be configured such that one end of a unit molecule (or a polymer of a unit molecule) of the first modified nucleic acid is directly connected to one end of a unit molecule (or a polymer of a unit molecule) Lt; / RTI >
- the first modified nucleic acid and the second modified nucleic acid included in the connection portion 400 may be connected through a specific compound.
- the connection unit 400 connects one end of the unit molecule of the first modified nucleic acid (or the polymer of the unit molecule) and one end of the unit molecule of the second modified nucleic acid (or the polymer of the unit molecule) Or the like.
- connection unit 400 may be configured such that unit molecules of the first modified nucleic acid and unit molecules of the second modified nucleic acid are connected.
- the connection unit 400 may be configured such that at least a portion of the base is modified with a unit molecule of DNA and a unit molecule of RNA in which at least a portion of the base is modified.
- the connection unit 400 may be configured such that at least a portion of the base is modified by unit molecules of the RNA and at least a portion of the base is connected to the unit molecules of the RNA through specific compounds.
- connection unit 400 may be configured such that a unit molecule of the first modified nucleic acid and a unit molecule of the second modified nucleic acid are connected.
- the connection unit 400 may be configured such that at least a portion of the base is modified, and a unit molecule of DNA is modified so that at least a part of the polymer and the base of the DNA are modified.
- the connection unit 400 may be configured such that at least a part of the base is modified, and a unit molecule of the DNA in which at least a part of the polymer and base of the DNA is modified is connected through a specific compound.
- connection unit 400 may be configured such that a polymer of a unit molecule of the first modified nucleic acid and a polymer of a unit molecule of the second modified nucleic acid are connected.
- the connection unit 400 may be configured such that a polymer of a unit molecule of DNA in which at least a portion of the base is modified and a polymer of a unit molecule of RNA in which at least a portion of the base is modified are connected.
- the connection unit 400 may be configured such that at least a part of the base is modified, and a polymer of the unit molecule of the RNA and a polymer of the unit molecule of the RNA in which at least a part of the base is modified are connected through a specific compound.
- connection unit 400 may include a unit molecule of a nucleic acid analogue.
- connection unit 400 may include a unit molecule of PNA (peptide nucleic acid), which is an example of a nucleic acid analogue.
- the unit molecule of the PNA may be a substance represented by the above formula (3).
- connection unit 400 may include a unit molecule of LNA (Locked Nucleic Acid), which is an example of a nucleic acid analogue.
- LNA Locked Nucleic Acid
- the unit molecule of the LNA may be a substance represented by the following chemical formula (4).
- connection unit 400 may include a unit molecule of BNA (Bridged Nucleic Acid), which is an example of a nucleic acid analogue.
- BNA Binary Nucleic Acid
- the unit molecule of the BNA may be a substance represented by the above formula (5).
- connection unit 400 may include a unit molecule of HNA (Hexose nucleic acid), which is an example of a nucleic acid analogue.
- the unit molecule of the HNA may be a substance represented by the above formula (6).
- connection unit 400 may include a unit molecule of GNA (Glycol nucleic acid), which is an example of a nucleic acid analogue.
- GNA Glycol nucleic acid
- the unit molecule of the GNA may be a substance represented by the above formula (7).
- connection unit 400 may include a unit molecule of Threose nucleic acid (TNA), which is an example of a nucleic acid analogue.
- TNA Threose nucleic acid
- the unit molecule of the TNA may be a substance represented by the following formula (8).
- connection unit 400 may include unit molecules of cyclohexene nucleic acid (CeNA), which is an example of a nucleic acid analogue.
- CeNA cyclohexene nucleic acid
- the unit molecule of the CeNA may be a substance represented by the above formula (9).
- connection unit 400 may include a unit molecule of a nucleic acid analogue.
- connection unit 400 may be composed of a unit molecule of a nucleic acid analog.
- connection unit 400 may include a unit molecule of the LNA.
- connection portion 400 may be composed of a polymer of a unit molecule of a nucleic acid analog.
- connection unit 400 may be composed of a polymer of a unit molecule of PNA.
- connection unit 400 may include a unit molecule of the first nucleic acid analog and a unit molecule of the second nucleic acid analog.
- the connection portion 400 may include at least a first nucleic acid analog and a second nucleic acid analog.
- connection unit 400 may be directly connected.
- the connection unit 400 is provided in a form in which one end of the unit molecule of the first nucleic acid analog (or the polymer of the unit molecule) and one end of the unit molecule of the second nucleic acid analog (or the polymer of the unit molecule) are directly connected .
- connection unit 400 may be configured such that one end of the unit molecule of the first nucleic acid analog (or the polymer of the unit molecule) and one end of the unit molecule of the second nucleic acid analog (or the polymer of the unit molecule) Lt; / RTI >
- connection unit 400 may be configured such that unit molecules of the first nucleic acid analogue and unit molecules of the second nucleic acid analogue are connected.
- connection unit 400 may be configured such that a unit molecule of a PNA and a unit molecule of an LNA are connected to each other.
- connection unit 400 may be configured such that a unit molecule of the first nucleic acid analog and a unit molecule of the second nucleic acid analog are connected.
- the connection unit 400 may be configured such that a polymer of a unit molecule of TNA and a unit molecule of GNA are connected.
- the connection unit 400 may be configured such that the polymer of the unit molecule of CeNA and the unit molecule of CeNA are connected through a specific compound.
- connection unit 400 may be configured such that a polymer of the unit molecule of the first nucleic acid analogue and a polymer of the unit molecule of the second nucleic acid analogue are connected.
- the connection unit 400 may be configured such that a polymer of a unit molecule of BNA and a polymer of a unit molecule of HNA are connected.
- the connection unit 400 may be configured such that the polymer of the unit molecule of the LNA and the polymer of the unit molecule of the LNA are connected to each other through the specific compound.
- connection unit 400 may include a unit molecule of a nucleic acid analog and a unit molecule of the modified nucleic acid.
- the connection portion 400 may include at least a first nucleic acid analog and a first modified nucleic acid.
- connection unit 400 is formed by directly connecting one end of the unit molecule (or the polymer of the unit molecule) of the first nucleic acid analog and the unit molecule (or the polymer of the unit molecule) of the first modified nucleic acid Can be provided.
- the first nucleic acid analogue and the first modified nucleic acid contained in the connection portion 400 may be connected through a specific compound.
- the connection unit 400 connects one end of the unit molecule (or the polymer of the unit molecule) of the first nucleic acid analogue and one end of the unit molecule (or the polymer of the unit molecule) of the first modified nucleic acid through the specific compound And the like.
- connection unit 400 may be configured such that a unit molecule of a nucleic acid analogue and a unit molecule of a modified nucleic acid are connected.
- connection unit 400 may be configured such that at least a portion of the base is modified, and a unit molecule of the DNA and a unit molecule of the LNA are connected.
- connection unit 400 may be configured such that a polymer of the unit molecule of the nucleic acid analogue and a unit molecule of the modified nucleic acid are connected.
- connection unit 400 may be configured such that at least a portion of the base is modified with a unit molecule of RNA, and a polymer of PNA unit molecule is connected.
- connection unit 400 may be configured such that a unit molecule of the modified nucleic acid unit and a unit molecule of the nucleic acid analogue unit are connected.
- the connection unit 400 may be configured in such a manner that at least a portion of the base is modified, and a unit molecule of DNA and a unit molecule of GNA are connected.
- connection unit 400 may be configured such that a polymer of a unit molecule of a nucleic acid analogue and a polymer of a unit molecule of the modified nucleic acid are connected.
- the connection unit 400 may be configured such that a polymer of a unit molecule of RNA and a polymer of a unit molecule of CeNA are connected, at least a part of the base being modified.
- connection unit 400 The materials that can constitute the connection unit 400 and the configuration thereof have been specifically described so far. It should be understood, however, that this discloses only specific embodiments for facilitating understanding of the connection 400 according to the present application, and that the connection 400 should be construed to be limited to including the materials disclosed herein It is not.
- connection 400 may be interpreted to include compounds that are not disclosed herein.
- the linkage 400 can be interpreted to include unit molecules of nucleic acid analogs not disclosed herein.
- the unit molecule of the nucleic acid analogue may include a base, and at least a part of the constitution other than the base may be chemically modified as compared with the nucleotide.
- the connecting portion 400 can be interpreted as including at least one of Chemical Formulas 1 to 10 and Chemical Formulas 15 and 16 chemically modified to the extent that it is easily modified by those skilled in the art.
- connection portion 400 According to an embodiment of the present application, operation and examples of the connection portion 400 according to an embodiment of the present application will be specifically described.
- the terminology and function of the connection portion 400 will be more specifically understood in accordance with the material properties of the connection portion 400 and the operations and examples of the connection portion 400 described below.
- connection part 400 3.1.1.2 Operation of connection part 400
- connection unit 400 may connect the determination unit 100 and the tag unit 200.
- the connection unit 400 may be disposed between the determination unit 100 and the tag unit 200.
- the determination unit 100 and the tag unit 200 may be connected through a connection unit 400.
- connection unit 400 may be directly coupled to one end of the determination unit 100 or may be connected to a specific compound.
- the connection unit 400 may be connected to one end of the determination unit 100 based on a chemical coupling force.
- the connection unit 400 may be connected to one end of the crystal unit 100 based on at least one of a covalent bond, a hydrogen bond, an ionic bond, and a hydrophobic bond.
- connection unit 400 may be directly coupled to one end of the tag unit 200 or may be connected through a specific compound.
- the connection unit 400 may be connected to one end of the tag unit 200 based on a chemical coupling force.
- the connection unit 400 may be connected to one end of the tag unit 200 based on at least one of a covalent bond, a hydrogen bond, an ionic bond, and a hydrophobic bond.
- connection unit 400 may perform a function of separating the distance between the determination unit 100 and the tag unit 200.
- the connection unit 400 may perform a function of separating a distance between one end of the determination unit 100 and one end of the tag unit 200.
- connection part 400 separates the distance between the determination part 100 and the tag part 200, A DNA polymerase that reads the nucleotide sequence of the tag 100 can block the reading of the nucleotide sequence of the tag unit 200. This will be described in greater detail in block 3.1.1.3.1 “Blockers for PCR", below.
- connection unit 400 may be a blocker for PCR.
- the PCR blocker may block the information of one region connected to the PCR blocker from being acquired by another substance (for example, a DNA polymerase).
- the blocker for PCR can prevent the generation of an amplification product for the nucleotide sequence of one region connected to the PCR blocker.
- the PCR blocker can prevent the DNA polymerase from acquiring information of a certain region connected to the PCR blocker.
- amplification product herein may be a substance resulting from at least one cycle of PCR.
- amplification product may be a substance generated by performing at least two nucleotides through covalent bonding when performing PCR.
- amplification product for A in the present specification may refer to a substance produced so as to have a nucleotide sequence complementary to the nucleotide sequence of A.
- the term “amplification product for A” may be a nucleotide or polynucleotide generated so as to have a nucleotide sequence complementary to the nucleotide sequence of A.
- the polynucleotide may be generated by extending at least a H group of a sugar of one nucleotide and OH in a phosphate group of another nucleotide by covalent bonding.
- connection unit 400 can prevent the amplification product from being generated for the crystal unit 100 connected to the connection unit 400.
- connection unit 400 may prevent the amplification product from being generated for the tag unit 200 connected to the connection unit 400.
- connection unit 400 may have a predetermined length.
- connection portion 400 may be formed to have a length exceeding at least 1 ohm Strom.
- connection portion 400 may be formed to have a length exceeding at least 3.4 angstroms.
- connection portion 400 may be formed to have a length exceeding at least 5 angstroms.
- connection portion 400 may be formed to have a length exceeding at least one mer.
- connection portion 400 may have a length of at least 3 mers.
- connection portion 400 may have a length of at least 5 mers.
- connection unit 400 may include a unit molecule of nucleic acid from which a base is removed.
- the connection unit 400 may be a polymer of a unit molecule of DNA from which a base is removed.
- connection unit 400 may be a polymer of a unit molecule of the RNA from which the base is removed.
- connection unit 400 may include a unit molecule of nucleic acid modified with a base.
- the connection unit 400 may be a polymer of a unit molecule of DNA in which a base is modified.
- the connection unit 400 may be a polymer of a unit molecule of a RNA modified base.
- connection unit 400 may include a unit molecule of a nucleic acid analogue.
- the connection part 400 may be a polymer of a unit molecule of PNA.
- the connection unit 400 may be a polymer of a unit molecule of LNA.
- connection portion 400 may be a chain-like structure including carbon.
- connection part 400 may be polyethyleneglycol (PEG).
- nucleic acid complex 1 including the crystal unit 100, the tag unit 200 and the connection unit 400, the respective components (i.e., the crystal unit 100, the tag unit 200, 400)) have been described in detail.
- FIG. 6 is a diagram for explaining the positional relationship among the components of the nucleic acid complex 1 according to one embodiment of the present application.
- the nucleic acid complex 1 may include a crystal part 100, a tag part 200 and a connection part 400.
- the crystal unit 100, the tag unit 200, and the connection unit 400 of the nucleic acid complex 1 may have a predetermined positional relationship.
- the determination unit 100, the tag unit 200, and the connection unit 400 may be connected.
- the side to which the crystal unit 100 of the connection unit 400 is connected may be different from the side to which the tag unit 200 of the connection unit 400 is connected.
- the connection unit 400 may be disposed between the determination unit 100 and the tag unit 200.
- One end of the crystallization part 100 may be directly connected to one end of the connection part 400 or may be connected with a specific compound.
- One end of the tag unit 200 may be directly connected to the other end of the connection unit 400 (one end different from the end of the connection unit 400), or may be connected through a specific compound.
- one end of the crystal unit 100 is directly connected to one end of the connection unit 400 according to a chemical coupling, and one end of the tag unit 200 is directly connected to the other end of the connection unit 400 .
- connection unit 400 is directly connected to one end of the determination unit 100, and the other end of the connection unit 400 is connected to one end of the tag unit 200 through a specific compound.
- connection unit 400 may be connected to one end of the crystal unit 100 through a specific compound, and the other end of the connection unit 400 may be directly connected to one end of the tag unit 200 .
- connection unit 400 is connected to one end of the determination unit 100 through a specific compound, and the other end of the connection unit 400 is connected to one end of the tag unit 200 through a specific compound .
- one end of the tag unit 200 is connected to one end of the connection unit 400, and the other end of the connection unit 400 (the end of the tag unit 200)
- the determination unit 100, the tag unit 200, and the connection unit 400 may be connected to each other (see FIG. 6 (a)).
- connection part 400 is connected to the 3 'end of the determination part 100, and the other end of the connection part 400 is connected to the 3'
- the determination unit 100, the tag unit 200, and the connection unit 400 may be connected (see FIG. 6 (b)).
- connection part 400 is connected to the 5 'end of the crystal part 100, and the other end of the connection part 400 is connected to the 5'
- the determination unit 100, the tag unit 200, and the connection unit 400 may be connected (see FIG. 6 (c)).
- connection part 400 is connected to the 3'-end of the crystal part 100, and the other end of the connection part 400 is connected to the 3'- The determination unit 100, the tag unit 200, and the connection unit 400 may be connected (see FIG. 6 (d)).
- nucleic acid complex 1 according to the second embodiment of the present application has been described.
- the nucleic acid complex 1 according to the third embodiment described below is the same except that it further includes the label portion 300 in comparison with the nucleic acid complex 1 described above. Therefore, in describing the third embodiment, the same reference numerals are assigned to the same components as those of the above-described embodiment, and a detailed description thereof is omitted.
- FIG. 7 is a diagram for explaining the nucleic acid complex 1 according to the third embodiment of the present application.
- the nucleic acid complex 1 may include a crystal portion 100, a tag portion 200, a label portion 300, and a connection portion 400.
- FIG. 8 is a diagram for explaining the positional relationship among the components of the nucleic acid complex 1 according to one embodiment of the present application.
- the nucleic acid complex 1 may include a crystal unit 100, a tag unit 200, a label unit 300, and a connection unit 400.
- the determination unit 100, the tag unit 200, the label unit 300, and the connection unit 400 may be connected based on a chemical bonding force.
- the determination unit 100, the tag unit 200, the label unit 300, and the connection unit 400 may be connected based on at least one of covalent bonding, hydrogen bonding, ionic bonding, and hydrophobic bonding.
- the crystal unit 100, the tag unit 200, the label unit 300, and the connection unit 400 of the nucleic acid complex 1 may have a predetermined positional relationship.
- a nucleic acid complex 1 in the form of a label portion 300, a tag portion 200, a connection portion 400, and a crystal portion 100 may be provided in this order (see FIG. 8 a)).
- the label unit 300 may be connected to one end of the tag unit 200.
- One end of the label unit 300 may be connected to one end of the tag unit 200 by chemical bonding.
- One end of the tag unit 200 and one end of the label unit 300 may be directly connected.
- one end of the tag unit 200 and one end of the label unit 300 may be connected through a specific compound.
- connection unit 400 may be connected to the other end of the tag unit 200 (i.e., the other end of the tag unit 200).
- One end of the connection unit 400 may be connected to the other end of the tag unit 200 by chemical coupling.
- the other end of the tag unit 200 and one end of the connection unit 400 may be directly connected.
- the other end of the tag unit 200 and one end of the connection unit 400 may be connected through a specific compound.
- the determination unit 100 may be connected to the other end of the connection unit 400 (i.e., the other end of the connection unit 400).
- One end of the crystal unit 100 may be connected to the other end of the connection unit 400 according to a chemical coupling.
- the other end of the connection part 400 and one end of the determination part 100 may be directly connected.
- the other end of the connection part 400 and one end of the determination part 100 may be connected through a specific compound.
- the nucleic acid complex 1 of FIGS. 6 (a) to 6 (d) further includes a label portion 300, and the label portion 300, the tag portion 200, a connecting part 400, and a crystal part 100 in this order.
- a nucleic acid complex 1 in the form of a tag portion 200, a label portion 300, a connection portion 400, and a determination portion 100 may be provided in this order (see FIG. 8 b)).
- the tag unit 200 may be connected to one end of the label unit 300.
- One end of the tag unit 200 may be connected to one end of the label unit 300 by chemical coupling.
- One end of the label unit 300 and one end of the tag unit 200 may be directly connected.
- one end of the label portion 300 and one end of the tag portion 200 may be connected through a specific compound.
- connection unit 400 may be connected to the other end of the label unit 300 (i.e., the other end of the label unit 300).
- One end of the connection unit 400 may be connected to the other end of the label unit 300 by chemical bonding.
- the other end of the label unit 300 and one end of the connection unit 400 may be directly connected.
- the other end of the label portion 300 and one end of the connection portion 400 may be connected through a specific compound.
- the determination unit 100 may be connected to the other end of the connection unit 400 (i.e., the other end of the connection unit 400).
- One end of the crystal unit 100 may be connected to the other end of the connection unit 400 according to a chemical coupling.
- the other end of the connection part 400 and one end of the determination part 100 may be directly connected.
- the other end of the connection part 400 and one end of the determination part 100 may be connected through a specific compound.
- the nucleic acid complex 1 according to an embodiment of the present invention further includes a label portion 300, and the tag portion 200, the label portion 300, a connecting part 400, and a crystal part 100 in this order.
- a nucleic acid complex 1 in the form of a tag portion 200, a connection portion 400, a label portion 300, and a determination portion 100 may be provided in this order (see FIG. 8 c).
- the tag unit 200 may be connected to one end of the connection unit 400.
- One end of the tag unit 200 may be connected to one end of the connection unit 400 by chemical coupling.
- One end of the connection part 400 and one end of the tag part 200 may be directly connected.
- one end of the connection unit 400 and one end of the tag unit 200 may be connected through a specific compound.
- the label unit 300 may be connected to the other end of the connection unit 400 (i.e., the other end of the connection unit 400). One end of the label unit 300 may be connected to the other end of the connection unit 400 according to a chemical coupling. The other end of the connection part 400 and one end of the label part 300 may be directly connected. Alternatively, the other end of the connection part 400 and one end of the label part 300 may be connected through a specific compound.
- the determination unit 100 may be connected to the other end of the label unit 300 (i.e., the other end of the label unit 300).
- One end of the crystallization part 100 may be connected to the other end of the label part 300 by chemical bonding.
- the other end of the label unit 300 and one end of the determination unit 100 may be directly connected.
- the other end of the label portion 300 and one end of the determination portion 100 may be connected through a specific compound.
- the nucleic acid complex 1 further includes a label portion 300, and the tag portion 200, the connection portion 400 ), A label portion (300), and a crystal portion (100).
- a nucleic acid complex 1 in the form of a tag portion 200, a connection portion 400, a crystal portion 100, and a label portion 300 may be provided in this order (see FIG. 8 d)).
- the tag unit 200 may be connected to one end of the connection unit 400.
- One end of the tag unit 200 may be connected to one end of the connection unit 400 by chemical coupling.
- One end of the connection part 400 and one end of the tag part 200 may be directly connected.
- one end of the connection unit 400 and one end of the tag unit 200 may be connected through a specific compound.
- the determination unit 100 may be connected to the other end of the connection unit 400 (i.e., the other end of the connection unit 400).
- One end of the crystal unit 100 may be connected to the other end of the connection unit 400 according to a chemical coupling.
- the other end of the connection part 400 and one end of the determination part 100 may be directly connected.
- the other end of the connection part 400 and one end of the determination part 100 may be connected through a specific compound.
- the label unit 300 may be connected to the other end of the determination unit 100 (i.e., the other end of the determination unit 100). One end of the label unit 300 may be connected to the other end of the determination unit 100 by chemical bonding. The other end of the determination unit 100 and one end of the label unit 300 may be directly connected. Alternatively, the other end of the determination unit 100 and one end of the label unit 300 may be connected through a specific compound.
- the nucleic acid complex 1 further includes a label portion 300, and the tag portion 200, the connection portion 400 ), The crystal section (100), and the label section (300) in this order.
- nucleic acid complex (1) according to some embodiments of the present application has been specifically disclosed.
- the nucleic acid complex (1) according to the present application may be one in which one of the above-mentioned respective constituent elements is omitted, another constituent element is further included, or a plurality of specific constituent elements and / . ≪ / RTI >
- nucleic acid conjugate pair 10 comprising at least two or more nucleic acid complexes (1) will be described in detail.
- FIG 9 is a view for explaining a nucleic acid complex pair 10 according to an embodiment of the present application.
- the nucleic acid conjugate pair 10 may comprise at least a first nucleic acid complex 110 and a second nucleic acid complex 120.
- the nucleic acid complex pair 10 may be composed of a first nucleic acid complex 110 and a second nucleic acid complex 120.
- the nucleic acid complex pair 10 may be provided in a pair with the first nucleic acid complex 110 and the second nucleic acid complex 120.
- the first nucleic acid complex 110 may be any one of the nucleic acid complexes 1 of the nucleic acid complexes 1 according to one embodiment of the present application.
- the first nucleic acid complex 110 may include at least one of a first crystallization part 111, a first tag part 112, a first connection part 114 and a first label part 113 .
- the first nucleic acid complex 110 may include a first crystallization part 111, a first tag part 112, a first label part 113, and a first connection part 114.
- the first nucleic acid complex 110 may include a first crystallographic portion 111, a first tag portion 112, and a first label portion 113.
- the first nucleic acid complex 110 may include a first crystal portion 111, a first tag portion 112, and a first connection portion 114.
- the first nucleic acid complex 110 may include a first crystal portion 111 and a first tag portion 112.
- the second nucleic acid complex 120 may be any one of the nucleic acid complexes 1 of the nucleic acid complexes 1 according to one embodiment of the present application.
- the second nucleic acid complex 120 may include at least one of a second crystal portion 121, a second tag portion 122, a second connection portion 124, and a second label portion 123 .
- the second nucleic acid complex 120 may include a second crystal portion 121, a second tag portion 122, a second label portion 123, and a second connection portion 124.
- the second nucleic acid complex 120 may include a second crystal portion 121, a second tag portion 122, and a second label portion 123.
- the second nucleic acid complex 120 may include a second crystal portion 121, a second tag portion 122, and a second connection portion 124.
- the second nucleic acid complex 120 may include a second crystal portion 121 and a second tag portion 122.
- the components of the first nucleic acid complex 110 and the second nucleic acid complex 120 are identical.
- the first nucleic acid complex 110 may have the same configuration as the second nucleic acid complex 120.
- the second nucleic acid complex 120 may also include the second crystal part 121 and the second And a tag unit 122.
- the composite 120 may also include a second crystal portion 121, a second tag portion 122, a second label portion 123, and a second connection portion 124.
- the first nucleic acid complex 110 may have a different configuration from the second nucleic acid complex 120.
- the second nucleic acid complex 120 may include the second A determination unit 121 and a second tag unit 122.
- the second nucleic acid complex 120 may include a second crystal A second tag portion 122, a second label portion 123, and a second connection portion 124.
- the positional relationship between the constituent elements of the first nucleic acid complex 110 and the constituent elements of the second nucleic acid complex 120 may be the same.
- the positional relationship between the constituent elements of the first nucleic acid complex 110 and the second nucleic acid complex 120 may have the same positional relationship.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 include the crystal portion 100, the tag portion 200, and the label portion 300
- the first nucleic acid complex 110 And the second nucleic acid complex 120 may be connected in the order of the crystal unit 100, the tag unit 200, and the label unit 300.
- the positional relationship of the constituent elements of the first nucleic acid complex 110 and the constituent elements of the second nucleic acid complex 120 may be different.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may be partially different in configuration so that the positional relationship between the components of the first nucleic acid complex 110 and the second nucleic acid complex The positional relationship of the components of the display device 120 may be different.
- the first nucleic acid complex 110 includes a first crystal section 111, a first tag section 112, a first label section 113, and a first connection section 114
- the complex 120 includes the second crystal part 121, the second tag part 122 and the second label part 123
- the first nucleic acid complex 110 includes the first crystal part 111
- the second nucleic acid complex 120 is connected to the first connection part 114 in the order of the first tag part 112 and the first label part 113.
- the second nucleic acid complex 120 is in the form of a second crystal part 121, 122, and a second label unit 123 in that order.
- the positional relationship between the constituent elements of the first nucleic acid complex 110 and the second nucleic acid complex may be different.
- first nucleic acid complex 110 and the second nucleic acid complex 120 include the crystal portion 100, the tag portion 200, the label portion 300, and the connection portion 400
- 1 nucleic acid complex 110 is connected in the order of a crystal unit 100, a connection unit 400, a tag unit 200 and a label unit 300.
- the second nucleic acid complex 120 includes a crystal unit 100, The label unit 300, the connection unit 400, and the tag unit 200 in this order.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may have the same function between the corresponding components.
- the component corresponding to the first determining unit 111 may be the second determining unit 121.
- the component corresponding to the first tag unit 112 may be the second tag unit 122.
- the component corresponding to the first label portion 113 may be the second label portion 123.
- the component corresponding to the first connection part 114 may be the second connection part 124.
- nucleic acid conjugate pair 10 having the same function between the corresponding components between the first nucleic acid complex 110 and the second nucleic acid complex 120 includes the first crystal portion 111 and the second crystal portion 121 function as a PCR primer and the first label portion 113 and the second label portion 123 generate signals (e.g., emit light or perform an oxidation / reduction reaction ) Function.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may comprise functional components that are mutually corresponding to each other.
- the first label portion 113 performs a function of generating a specific signal (e.g., emits light of a first wavelength band), and the second label portion 123 absorbs the specific signal E.g., absorbing light in the first wavelength band).
- a specific signal e.g., emits light of a first wavelength band
- the second label portion 123 absorbs the specific signal E.g., absorbing light in the first wavelength band
- the first nucleic acid complex 110 and the second nucleic acid complex 120 include at least one component having a different inter-component function from each other, the first nucleic acid complex 110 and the second nucleic acid complex 120 120 may include at least one component having the same function as the corresponding component.
- the first label portion 113 performs a function of generating a specific signal (e.g., emits light of a first wavelength band), and the second label portion 123 absorbs the specific signal E.g., absorbing light in the first wavelength band).
- the first determining unit 111 and the second determining unit 121 may function as a PCR primer.
- first nucleic acid complex 110 and the second nucleic acid complex 120 include at least one component having a different inter-component function from each other, the first nucleic acid complex 110 and the second nucleic acid The complexes 120 may not include at least one component having the same function between the corresponding components.
- the first label portion 113 performs a function of generating a specific signal (e.g., emits light of a first wavelength band), and the second label portion 123 absorbs the specific signal E.g., absorbing light in the first wavelength band).
- the first tag unit 112 performs a function of a PCR clamping probe, and the second tag unit 122 may not perform a function of a PCR clamping probe.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may have the same constituent material between the corresponding constituent elements.
- first crystal unit 111 and the second crystal unit 121 are made of a polymer of unit molecules of DNA
- the first tag portion 112 and the second tag portion 122 may be composed of the polymer of Formula 10 above.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may comprise different constituent elements of the corresponding constituent components.
- the first crystallization part 111 is made of a polymer of unit molecules of DNA, and the second crystallization part 121 (a component corresponding to the first crystallization part 111) Polymer.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may include at least one component having the same constituent material between the corresponding constituent elements.
- the first crystallization part 111 is made of a polymer of unit molecules of DNA, and the second crystallization part 121 (a component corresponding to the first crystallization part 111) Polymer.
- the first tag portion 112 and the second tag portion 122 may be composed of the compound 10 described above.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 correspond to each other and at least one constituent is different from each other, the first nucleic acid complex 110 and the second nucleic acid complex 120 may not include at least one component having the same constituent material between the corresponding constituent elements.
- the first crystallization part 111 is made of a polymer of unit molecules of DNA, and the second crystallization part 121 (a component corresponding to the first crystallization part 111) Polymer.
- the first tag portion 112 may be composed of a polymer of unit molecules of DNA
- the second tag portion 122 may be composed of a polymer of PNA unit molecules.
- the first label portion 113 may be composed of fluorescent molecules
- the second label portion 123 may be composed of a quencher molecule.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may have the same physical characteristics between the corresponding components.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may have different physical characteristics between corresponding components.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 have different physical characteristics between corresponding components
- the first nucleic acid complex 110 and the second nucleic acid complex 120 correspond to each other And may include at least one component having the same physical characteristics as the components.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may be mutually different from each other But may not include at least one component having the same physical characteristics among the corresponding components.
- the physical properties may be physical length, weight, optical properties (e.g., wavelength band, intensity), cohesion with specific materials, color, thermal conductivity and / or strength.
- first nucleic acid complex 110 and the second nucleic acid complex 120 will be described with respect to the length of the above various physical characteristics.
- first nucleic acid complex 110 and the second nucleic acid complex 120 related to other properties of the physical properties will be omitted due to limitations of the specification, it will be understood by those skilled in the art that, The first nucleic acid complex 110 and the second nucleic acid complex 120 of the present invention will be easily understood and therefore the physical characteristics should not be limited in length in interpreting the scope of the present specification.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may have the same physical length between the corresponding components.
- the first crystallization part 111 is a single-stranded nucleic acid (for example, DNA) having a length of 10 mer
- the second crystallization part 121 is also a single-stranded nucleic acid having a length of 10 mer DNA).
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may have physical lengths corresponding to each other.
- the first tag portion 112 is a single-stranded nucleic acid (e.g., DNA) having a length of 10 mer
- the second tag portion 122 is a single-stranded nucleic acid having a length of 7 mer ).
- the first nucleic acid complex 110 and the second nucleic acid complex 120 include at least one component having a different physical length between corresponding components
- the composite 120 may include at least one component having the same physical length between corresponding components.
- the second tag portion 122 may be a single-stranded nucleic acid (e.g., PNA) Lt; / RTI >
- the first determining unit 111 is a single-stranded nucleic acid (e.g., DNA) having a length of 10 mer
- the second determining unit 121 may be a single stranded nucleic acid (e.g., DNA) Lt; / RTI >
- first nucleic acid complex 110 and the second nucleic acid complex 120 include at least one component having a physical length different from that of the corresponding component
- first nucleic acid complex 110 and the second nucleic acid complex 120 2 nucleic acid complexes 120 may not include at least one component having the same physical length between corresponding components.
- the second tag portion 122 may be a single-stranded nucleic acid (e.g., PNA) Lt; / RTI >
- the first crystal unit 111 is a single-stranded nucleic acid (e.g., DNA) having a length of 17 mer
- the second determining unit 121 may be a single stranded nucleic acid (e.g., DNA) Lt; / RTI >
- the structures of the first nucleic acid complex 110 and the second nucleic acid complex 120 included in the nucleic acid complex pair 10 have been specifically described.
- nucleic acid complex pair 10 This means that specific embodiments for facilitating understanding of the nucleic acid complex pair 10 according to the present application are disclosed and that the nucleic acid complex pair 10 should be interpreted only in the constitution disclosed in this specification It is not.
- the nucleic acid conjugate pair 10 may be provided in a form including an additional nucleic acid complex 1 in addition to the first nucleic acid complex 110 and the second nucleic acid complex 120.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 included in the nucleic acid complex pair 10 may have distinctive characteristics other than those described above, And the second nucleic acid complex 120 may have characteristics in which at least two of the characteristics described above are distinguished.
- nucleic acid complex pair 10 operations and examples of the nucleic acid complex pair 10 according to an embodiment of the present application will be specifically described. According to the structure of the nucleic acid complex pair 10 already described and the operation and examples of the nucleic acid complex pair 10 described below, the terminology and function of the nucleic acid complex pair 10 will be more specifically understood It will be possible.
- the nucleic acid complex pair 10 is composed of the first nucleic acid complex 110 and the second nucleic acid complex 120 and the first nucleic acid complex 110 and the second nucleic acid complex 120 are the same,
- the second nucleic acid complex 120 includes a first crystallization part 111, a first connection part 114, a first tag part 112 and a first label part 113,
- the second connector portion 121, the second connector portion 124, the second tag portion 122, and the second label portion 123 will be described.
- nucleic acid complex pair 10 used in the various embodiments described below should be construed in a limited manner in accordance with the above-described assumptions It does not.
- the first determination unit 111 may complementarily bind to a first target base sequence.
- first target base sequence may mean a base sequence complementary to at least a part of the base sequence of the first determinant 111.
- the complementary binding between the first determinant 111 and the first target base sequence may mean that at least one of the electrical, chemical, or physical properties is correspondingly associated.
- the first nucleotide sequence may be complementarily combined with the first nucleotide sequence through a hydrogen bond between the first target nucleotide sequence and at least one base of the first crystallization unit 111, can do.
- the binding force between the first determinant 111 and the first target base sequence is determined by the type of the unit molecule of the first determiner 111, the type of base of the unit molecule of the first determiner 111, 1 < / RTI > target sequence, and the number of bases involved in complementary binding to the target sequence.
- the unit molecule of the first crystal unit 111 binding to the first target base sequence is a unit molecule of the PNA
- the unit of the first crystal unit 111 binding to the first target base sequence may be stronger than when the molecule is composed of a unit molecule of DNA.
- the base contained in at least a part of the region of the first crystal unit 111 binding to the first target base sequence has a high content of C (cytosine) -G (guanine)
- the first target base sequence (Cytochrome) -G (guanine) contained in at least a part of the region of the first crystal unit 111 that is coupled to the first crystal unit 111 is low, Can be strong.
- the first crystal unit 111 when the base contained in at least a part of the region of the first crystal unit 111 binding to the first target base sequence is 10 bp, the first crystal unit 111, which binds to the first target base sequence, The bonding strength between the first target base sequence and the first crystal unit 111 may be stronger than that in the case where the base included in at least a part of the first target base sequence is 5 bp.
- the second determination unit 121 may complementarily bind to the second target base sequence.
- the term “second target base sequence” may mean a base sequence complementary to at least a part of the base sequence of the second crystallization unit 121.
- the complementary binding between the second determinant 121 and the second target base sequence may mean that at least one of the electrical, chemical, or physical properties is associated with each other.
- the second target base sequence and the second target base sequence are complementarily combined can do.
- the binding force between the second crystal unit 121 and the second target base sequence is determined by the type of the unit molecule of the second crystal unit 121, the type of the base unit molecule of the second crystal unit 121, Can be determined in relation to at least one of the number of bases involved in complementary binding with the base sequence.
- the unit molecule of the second crystal unit 121 binding to the second target base sequence is a unit molecule of the PNA
- the unit of the second crystal unit 121 binding to the second target base sequence may be stronger than when the molecule is composed of a unit molecule of DNA.
- the base contained in at least a partial region of the second crystal portion 121 binding to the second target base sequence has a high content of C (cytosine) -G (guanine)
- the second target base sequence (Cytosine) -G (guanine) contained in at least a part of the region of the second crystal unit 121 coupled to the second crystal unit 121 is lower than that of the second target base sequence and the second crystal unit 121, Can be strong.
- the second crystal unit 121 when the base included in at least a partial region of the second crystal unit 121 binding to the second target base sequence is 10 bp, the second crystal unit 121, which binds to the second target base sequence, The binding force between the second target base sequence and the second crystal unit 121 may be stronger than that in the case where the base included in at least a part of the target base sequence is 5 bp.
- the first crystal unit 111 and the second crystal unit 121 can specifically combine with each other.
- the first target nucleic acid including the first target base sequence complementarily binding to the first determiner 111 may include a second target base sequence complementary to the second determiner 121 And may be associated with a second target nucleic acid.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may act on mutually related materials.
- the first determination unit 111 and the second determination unit 121 may be related to each other.
- first crystallization part 111 and the second crystallization part 121 can specifically bind to the same nucleic acid.
- the first target nucleic acid and the second target nucleic acid may be the same.
- the first target base sequence and the second target base sequence may be contained in a single-stranded nucleic acid.
- first target base sequence and the second target base sequence are included in the double-stranded nucleic acid, and the first target base sequence and the second target base sequence may be included in any one of the double strands.
- the first target base sequence and the second target base sequence are included in the double-stranded nucleic acid, wherein the first target base sequence is contained in one strand of the double strand and the second target base sequence is included in the other of the double strands May be contained in one strand.
- FIGS. 10 and 11 are views for explaining the operation of the first determination unit 111 and the second determination unit 121 according to one embodiment of the present application.
- the first crystal unit 111 and the second crystal unit 121 may be complementarily coupled to an associated substance.
- the first crystal unit 111 and the second crystal unit 121 may be complementarily coupled to the same nucleic acid.
- the same nucleic acid may be a single-stranded nucleic acid comprising a first target base sequence and a second target base sequence.
- the first determining unit 111 is complementarily bound to the first target base sequence, and the first target base sequence
- the second determining unit 121 can complementarily bind to the second target base sequence in another region.
- the first tag portion 112 connected to the first determination portion 111 and the second tag portion 122 connected to the second determination portion 121 are connected to the first determination portion 111 or the second And can be positioned on one side with reference to the crystal unit 121 (see Fig. 10 (a)).
- the first determining unit 111 is complementarily bound to the first target base sequence, and the first target base sequence
- the second determining unit 121 can complementarily bind to the second target base sequence in a region other than the second target base sequence.
- the first tag portion 112 connected to the first determining portion 111 and the second tag portion 122 connected to the second determining portion 121 are connected to the first determining portion 111 and the second determining portion 121, And can be positioned on the other side with reference to the crystal unit 121 (see Fig. 10 (b)).
- the first crystal unit 111 and the second crystal unit 121 may be complementarily coupled to an associated substance.
- the first crystal unit 111 and the second crystal unit 121 may be complementarily coupled to the same nucleic acid.
- the first target base sequence and the second target base sequence are included in the double-stranded nucleic acid, and the first target base sequence and the second target base sequence can be included in any one of the double strands.
- the first determining unit 111 is complementarily bound to the first target base sequence, and the second target base sequence included in any one of the strands containing the first target base sequence has the second determining unit 121 Can be complementarily combined (see Fig. 11 (a)).
- the first crystal unit 111 and the second crystal unit 121 may be complementarily coupled to an associated substance.
- the first crystal unit 111 and the second crystal unit 121 may be complementarily coupled to the same nucleic acid.
- the first target base sequence and the second target base sequence are included in the double-stranded nucleic acid
- the first target base sequence is contained in one of the double strands
- the second target base sequence is included in the other of the double strands May be contained in one strand.
- One region of the nucleic acid corresponding to the first target base sequence and one region of the nucleic acid corresponding to the second target base sequence may exist in the form of a single strand.
- the first determining unit 111 is complementary to the first target base sequence, and the second target base sequence is included in one strand containing the first target base sequence and the second target base sequence included in the other strand.
- the portion 121 can be complementarily coupled (see Fig. 11 (b)).
- the first tag portion 112 connected to the first determination portion 111 and the second tag portion 112 connected to the second determination portion 121 are connected to each other,
- the tag unit 122 may be located at one side with respect to the first determination unit 111 or the second determination unit 121.
- the first target nucleic acid including the first target base sequence specifically binding to the first determinant section 111 and the second target base sequence specifically binding the second crystal section 121 May be posteriorly associated with the second target nucleic acid.
- the first determinant portion 111 specifically binds to the first target base sequence
- the nucleotide may be extended at the 3 ' end of the crystal unit 100 so as to have a sequence complementary to the sequence.
- the nucleotide sequence of the extended polynucleotide may include the second target nucleic acid.
- the polynucleotide generated at the 3 'end of the first determinant 111 may contain a second target base sequence.
- the first target nucleic acid and the second target nucleic acid may be posteriorly associated. Specific embodiments related to this can be understood in detail in Figs. 27 and 28 to be described below.
- the first tag portion 112 may complementarily bind to the nucleic acid complex 1 (i.e., the nucleic acid complex 1 other than the first nucleic acid complex 110).
- first tag portion 112 may be complementarily coupled to the second tag portion 122 of the second nucleic acid complex 120.
- the first tag portion 112 may include a compound having a chemical structure complementary to the chemical structure of the second tag portion 122.
- the second tag portion 122 may include a compound having a chemical structure complementary to the chemical structure of the first tag portion 112.
- the first tag unit 112 may include a base sequence complementary to the base sequence of the second tag unit 122.
- the first tag portion 112 may include a nucleic acid and / or a nucleic acid complex 1 including a base sequence complementary to the base sequence of the second tag portion 122.
- the second tag unit 122 may include a base sequence complementary to the base sequence of the first tag unit 112.
- the second tag portion 122 may include a nucleic acid and / or a nucleic acid complex 1 including a base sequence complementary to the base sequence of the first tag portion 112.
- the binding direction of the first nucleic acid complex 110 and the second nucleic acid complex 120 may vary depending on the direction in which the first tag portion 112 and the second tag portion 122 are joined. .
- first nucleic acid complex 110 and the second nucleic acid complex 110 may be formed in accordance with the arrangement of the elements exposed to the outside of the first tag portion 112 and the second tag portion 122 (that is, The binding direction of the nucleic acid complex 120 may be changed.
- the binding direction of the first nucleic acid complex 110 and the second nucleic acid complex 120 may vary depending on the base sequence of the first tag portion 112 and the second tag portion 122.
- the binding direction of the first nucleic acid complex 110 and the second nucleic acid complex 120 may be changed.
- FIG. 12 is a view for explaining the direction in which the first nucleic acid complex 110 and the second nucleic acid complex 120 are combined according to an embodiment of the present invention.
- the first tag portion 112 is configured such that one region of the first tag portion 112 adjacent to the first determination portion 111 is separated from the second crystal portion 121 And may include a complementary sequence to the second tag unit 122 so as to be complementarily combined with one region of the tag unit 122.
- the second tag portion 122 is formed in a region of the first tag portion 112 that is separated from the first crystal portion 111 by one region of the second tag portion 122 adjacent to the second crystal portion 121,
- the first tag portion 112 may include a complementary sequence so as to be complementarily joined.
- first nucleic acid complex 110 and the second nucleic acid complex 120 may be connected in the order of a crystal portion 100, a connection portion 400, a tag portion 200, and a label portion 300 Can be implemented.
- the first tag unit 112 may have a base sequence of CCCCCAAAA by listing the base sequences of the first tag unit 112 adjacent to the first connection unit 114.
- the second tag portion 122 may have a nucleotide sequence of TTTTGGGGG by listing the nucleotide sequences of the second tag portion 122 adjacent to the second linking portion 124.
- the first tag portion 112 may have a nucleotide sequence of 5'-CCCCCAAAA-3 ⁇ , which is arranged from the nucleotide sequence of the first tag portion 112 adjacent to the first connection portion 114.
- the second tag portion 122 may have a nucleotide sequence of 5'-TTTTGGGGG-3 ⁇ , starting from the nucleotide sequence of the second tag portion 122 adjacent to the second linking portion 124.
- the first tag portion 112 may have a nucleotide sequence of 3'-CCCCCAAAA-5 ', which is arranged from the nucleotide sequence of the first tag portion 112 adjacent to the first linking portion 114 have.
- the second tag unit 122 may have a nucleotide sequence of 3'-TTTTGGGGG-5 ⁇ , which is arranged from the nucleotide sequence of the second tag unit 122 adjacent to the second linking unit 124.
- One region of the second tag portion 122 adjacent to the second crystal portion 121 is complementarily coupled to one region of the first tag portion 112 spaced from the first crystal portion 111,
- the first determination unit 111 is positioned on one side with respect to the first tag unit 112 and the second tag unit 122 and the second determination unit 121 is positioned on the first side relative to the first tag unit 112 and the second tag unit 122, And may be positioned on the other side with respect to the tag portion 112 and the second tag portion 122.
- One region of the second tag portion 122 adjacent to the second crystal portion 121 is complementarily coupled to one region of the first tag portion 112 spaced from the first crystal portion 111, A portion of the first determination unit 111 connected to the first tag unit 112 is connected to the first tag unit 112 and the second tag unit 122, And a portion of the second crystal part 121 connected to the second tag part 122 is located on the first side of the first tag part 112 and the imaginary one side of the second tag part 122 Can be located on the second side as a reference. The first side and the second side may be on the other side with respect to the virtual one side.
- the first tag portion 112 is formed in such a manner that one region of the first tag portion 112 adjacent to the first determination portion 111 is adjacent to the second tag portion 112 adjacent to the second determination portion 121, And may include a complementary sequence to the second tag unit 122 so as to be complementarily combined with one region of the tag unit 122.
- the second tag portion 122 is formed in such a manner that one region of the second tag portion 122 adjacent to the second determination portion 121 is divided into one region of the first tag portion 112 adjacent to the first determination portion 111,
- the first tag portion 112 may include a sequence complementary to the first tag portion 112.
- first nucleic acid complex 110 and the second nucleic acid complex 120 may be connected in the order of a crystal portion 100, a connection portion 400, a tag portion 200, and a label portion 300 Can be implemented.
- the first tag unit 112 may have a base sequence of CCCCCAAAA by listing the base sequences of the first tag unit 112 adjacent to the first connection unit 114.
- the second tag portion 122 may have a nucleotide sequence of GGGGGTTTT from the nucleotide sequence of the second tag portion 122 adjacent to the second linking portion 124.
- the first tag portion 112 may have a nucleotide sequence of 5'-CCCCCAAAA-3 ⁇ , which is arranged from the nucleotide sequence of the first tag portion 112 adjacent to the first connection portion 114.
- the second tag portion 122 may have a nucleotide sequence of 3'-GGGGGTTTT-5 ', which is arranged from the nucleotide sequence of the second tag portion 122 adjacent to the second link portion 124.
- the first tag portion 112 may have a nucleotide sequence of 3'-CCCCCAAAA-5 ', which is arranged from the nucleotide sequence of the first tag portion 112 adjacent to the first linking portion 114 have.
- the second tag portion 122 may have a nucleotide sequence of 5'-GGGGGTTTT-3 ', which is arranged from the nucleotide sequence of the second tag portion 122 adjacent to the second link portion 124.
- One region of the second tag portion 122 adjacent to the second crystal portion 121 is complementarily coupled with one region of the first tag portion 112 adjacent to the first crystal portion 111,
- the first determination unit 111 is located at one side with respect to the first tag unit 112 and the second tag unit 122 and the second determination unit 121 is positioned at one side with respect to the first tag unit 112 and the second tag unit 122, The first tag portion 112 and the second tag portion 122 as a reference.
- One region of the second tag portion 122 adjacent to the second crystal portion 121 is complementarily coupled with one region of the first tag portion 112 adjacent to the first crystal portion 111, A portion of the first determination unit 111 connected to the first tag unit 112 is connected to a virtual surface of the first tag unit 112 and the second tag unit 122 And a portion of the second crystal portion 121 connected to the second tag portion 122 is located on the first side of the first tag portion 112 and the second tag portion 122, As shown in FIG. The first side and the second side may be on the same side with respect to the imaginary one side.
- the first nucleic acid complex 110 and the second nucleic acid complex 120 may be mutually connected to each other according to the nucleotide sequence of the first tag portion 112 and the second tag portion 122,
- the shape can be changed.
- the shape of the at least one target nucleic acid including the first target base sequence and the second target base sequence may be changed according to the base sequence of the first tag portion 112 and the second tag portion 122.
- the following table 1.2 will be concretely described in the formation of the secondary structure.
- the first tag portion 112 may include a region that is complementarily coupled to the second tag portion 122.
- the first tag portion 112 may be complementarily coupled to at least a portion of the second tag portion 122.
- the first tag portion 112 may be complementarily coupled to the entire region of the second tag portion 122.
- the base sequence of the first tag unit 112 may be complementary to the base sequence of the second tag unit 122.
- the first tag portion 112 may not have a base not coupled to the second tag portion 122.
- the base sequence of the second tag unit 122 may be complementary to the base sequence of the first tag unit 112.
- the second tag portion 122 may not have a base that is not coupled to the base sequence of the first tag portion 112.
- the first tag unit 112 has a base sequence complementary to the base sequence of the second tag unit 122, and the base sequence of the first tag unit 112 corresponds to the base sequence of the second tag unit 122 122) and at least one base sequence.
- the second tag part 122 has a base sequence complementary to the base sequence of the first tag part 112 and the base sequence of the second tag part 122 has a base sequence complementary to that of the first tag part 112
- the base sequence and the at least one base sequence may be different.
- the first tag portion 112 and the second tag portion 122 are formed based on a combination of mutually complementary base sequences included in the first tag portion 112 and the second tag portion 122, Can be mismatched and combined.
- first tag portion 112 may be complementarily coupled to a portion of the second tag portion 122.
- the base sequence of the first tag unit 112 may be complementary to a base sequence of the base sequence of the second tag unit 122.
- the first tag portion 112 may not have a base not coupled to the second tag portion 122.
- the second tag portion 122 may include a base that is not coupled to the base sequence of the first tag portion 112.
- FIG 13 is a view for explaining the coupling between the first tag portion 112 and the second tag portion 122 according to the embodiment of the present application.
- the first tag portion 112 may be complementarily coupled to a portion of the second tag portion 122.
- the base sequence of the first tag unit 112 and the base sequence of the second tag unit 122 are complementary to each other.
- the first tag unit 112 is connected to the second tag unit 122). ≪ / RTI >
- the region BR forming the complementary combination of the first tag portion 112 and the second tag portion 122 is a region complementary to the second tag portion 122 of the first tag portion 112 Can be relatively adjacent to a portion where the first tag portion 112 and the first determination portion 111 are connected, as compared with the region NBR where no bond is formed.
- the base that is complementarily coupled to the second tag portion 122 of the first tag portion 112 is not complementary to the second tag portion 122 of the first tag portion 112 Can be formed adjacent to the first crystal portion 111 as compared with a base (see Fig. 13 (a)).
- the region BR forming the complementary combination of the first tag portion 112 and the second tag portion 122 is a region complementary to the second tag portion 122 of the first tag portion 112
- the first tag portion 112 and the first determination portion 111 may be relatively spaced from each other at a portion where the first tag portion 112 and the first determination portion 111 are connected to each other.
- the base that is complementarily coupled to the second tag portion 122 of the first tag portion 112 is not complementary to the second tag portion 122 of the first tag portion 112 And may be spaced apart from the first crystal portion 111 as compared with the base (see FIG. 13 (b)).
- the region BR forming the complementary combination of the first tag portion 112 and the second tag portion 122 is complementarily coupled to the second tag portion 122 of the first tag portion 112 (NBR) which does not engage with the second tag portion 122 of the first tag portion 112 and the second region NBR which does not engage with the second tag portion 122 of the first tag portion 112.
- the first tag unit 112 includes a first target base sequence not complementary to the second tag unit 122, a second target base sequence complementary to the second tag unit 122, And a third base sequence that is not complementary to the second tag unit 122.
- the first tag unit 112 includes a first target base sequence not complementary to the second tag unit 122, a second target base sequence complementary to the second tag unit 122, , And a third base sequence that is not complementary to the second tag unit 122 (refer to FIG. 13 (c)).
- first tag portion 112 further includes a base sequence that is not complementary to the base sequence of the second tag portion 122, 1 tag unit 112 of the present invention.
- a base that is not complementarily coupled to the first tag portion 112 of the second tag portion 122 may be a complementary base to the first tag portion 112 and the second tag portion 122, May be formed in a first direction (e.g., a direction from the 5 'end to the 3' end with respect to the second tag portion 122) of the region joined with the second tag portion 122.
- a base that does not complementarily bind with the first tag portion 112 of the second tag portion 122 may be a complementary base to the first tag portion 112 and the second tag portion 122, May be formed in a second direction (e.g., a direction from the 3 'end to the 5' end with respect to the second tag portion 122) of the region coupled with the second tag portion 122.
- a base that is not complementarily coupled to the first tag portion 112 of the second tag portion 122 may be a complementary base to the first tag portion 112 and the second tag portion 122, (E.g., the direction from the 5 'end to the 3' end with respect to the second tag portion 122) and the second direction (e.g., the second tag portion 122 with respect to the second direction) The direction from the 3 'end to the 5' end).
- the first label portion 113 and the second label portion 123 may be involved in labeling the nucleic acid complex pair 10.
- the first label portion 113 may be involved in labeling the nucleic acid complex pair 10 through an action associated with the second label portion 123.
- the second label portion 123 may be involved in labeling the nucleic acid complex pair 10 through an action associated with the first label portion 113.
- the first label portion 113 and the second label portion 123 can be linked.
- the coupling between the first label portion 113 and the second label portion 123 (Hereinafter referred to as linkage) can be generated.
- first label portion 113 and the second label portion 123 may be connected to each other through complementary coupling between the first tag portion 112 and the second tag portion 122.
- the first label unit 113 and the second target base sequence 2 label portions 123 can be generated.
- a linking operation can be performed in such a manner that energy transfer occurs between the first label portion 113 and the second label portion 123.
- the first label unit 113 provides energy to the second label unit 123 and the second label unit 123 supplies energy to the first label unit 113.
- the second label portion 123 provides energy to the first label portion 113, and the first label portion 113 receives energy from the second label portion 123 Lt; / RTI >
- the first label portion 113 may provide energy to the second label portion 123, and may be provided with energy from the second label portion 123.
- the second label unit 123 may provide energy to the first label unit 113 and may receive energy from the first label unit 113.
- the physical properties may vary.
- the physical properties may be at least one of chemical, electrical, optical, and magnetic properties.
- the first label portion 113 and the second label portion 123 may include a first label portion 113 and a second label portion 123 depending on whether a linking action has occurred between the first label portion 113 and the second label portion 123.
- (UC) can be changed.
- the changed optical characteristics may be a change in intensity of light, a change in wavelength band of light, and the like.
- the first label portion 113 and the second label portion 123 are formed on the basis of physical properties that have changed depending on whether or not the linked action between the first label portion 113 and the second label portion 123 has occurred. It is possible to confirm whether or not the second label portion 123 is linked. As a result, the nucleic acid complex pair 10 can be labeled in such a manner that the information of the nucleic acid complex pair 10 is confirmed according to whether the first label portion 113 and the second label portion 123 are linked.
- the first label portion 113 is a fluorescent molecule that emits light in the first wavelength band when light is incident, and the second label portion 123 absorbs light when the light in the first wavelength band is incident. Is a black hole quan- tizer molecule.
- FIG 14 is a view for explaining the operation of the first label portion 113 and the second label portion 123 according to an embodiment of the present application.
- the "linkage effective distance (LD)" between the first label portion 113 and the second label portion 123 can be defined.
- linkage effective distance LD refers to a distance between the first label portion 113 and the second label portion 123, in which the linking action between the first label portion 113 and the second label portion 123 can be performed. May refer to a reference separation distance from the label portion 123.
- linkage effective distance LD refers to a distance from the first label portion 113 to the second label portion 113, from which the linking action between the first label portion 113 and the second label portion 123 can be performed, It may mean the critical distance of the degree of separation of the label portion 123.
- the " linkage effective distance LD" refers to a distance from the second label portion 123 to the first label portion 113, from which the linking action between the first label portion 113 and the second label portion 123 can be performed, It may mean the critical distance of the degree of separation of the label portion 113.
- the linking action effective distance LD can be determined based on the properties of the first label portion 113 and the second label portion 123.
- the linkage effective distance LD can be determined according to the characteristics between the fluorescent molecule and the quencher molecule. For example, when the quencher molecule has a characteristic that a coupling action is performed when the molecule is within a range of 100 angstroms from the fluorescent molecule, the coupling action effective distance LD may be 100 angstroms.
- the first label portion 113 and the second label portion 123 are disposed adjacent to each other so that the distance between the first label portion 113 and the second label portion 123 is smaller than the link effective distance LD. , The first label portion 113 and the second label portion 123 can perform a linking operation (see FIG. 14 (a)).
- the first label portion 113 and the second label portion 123 When the first label portion 113 and the second label portion 123 perform the combined action, the first label portion 113 emits light of the first wavelength band, and the second label portion 123 emits light of the first wavelength band. It can absorb light of one wavelength. As a result, when light of the unit cell UC including the first label portion 113 and the second label portion 123 is detected through the optical device, the light of the first wavelength range from the unit cell UC It may not be detected. Or as a result of detecting light of the unit cell UC including the first label portion 113 and the second label portion 123 through the optical device, The intensity of the light of the wavelength band can be reduced.
- the first label portion 113 and the second label portion 123 are spaced apart and the distance between the first label portion 113 and the second label portion 123 exceeds the linkage effective distance LD ,
- the first label unit 113 and the second label unit 123 may not perform a linking operation (see FIG. 14 (b)).
- the first label portion 113 and the second label portion 123 do not perform the linking action, the first label portion 113 emits light of the first wavelength band, and the second label portion 123 emits light of the first wavelength band. It may not emit light of one wavelength band.
- a unit cell UC for example, a tube
- the light of the first wavelength range can be detected.
- the distance between the first label portion 113 and the second label portion 123 is determined based on whether the first tag portion 112 and the second tag portion 122 are engaged or not It can be different.
- the distance between the first label portion 113 and the second label portion 123 can be determined based on whether or not the first tag portion 112 and the second tag portion 122 are engaged.
- first label portion 113 and the second label portion 123 may be disposed adjacent to each other.
- first tag portion 112 and the second tag portion 122 are complementarily coupled to each other, the first label portion 113 and the second tag portion 122 connected to the first tag portion 112, And the second label portion 123 connected to the second label portion 123 can be disposed adjacent to each other.
- first label portion 113 and the second label portion 123 may be spaced apart from each other.
- first label portion 113 and the second tag portion 122 connected to the first tag portion 112, The second label portion 123 may be spaced apart.
- the distance between the first label portion 113 and the second label portion 123 is determined based on whether or not the first tag portion 112 and the second tag portion 122 are engaged. Whether or not the linkage operation is performed can be determined.
- F 15 is a graph of a fluorescence value (F) per wavelength band WL according to the coupling action between the first label portion 113 and the second label portion 123, according to an embodiment of the present application.
- the linking action between the first label portion 113 and the second label portion 123 may cause a change in optical characteristics.
- the optical characteristics of the unit cell UC including the first label portion 113 and the second label portion 123 after the interlocking action between the first label portion 113 and the second label portion 123 are different from each other .
- the first label portion 113 and the second label portion 123 123) can cause a change in the wavelength band of the detected signal (e.g., the wavelength band of light).
- the first label portion 113 and the second label portion 123) can cause a change in the intensity of the signal at a certain wavelength band.
- the first label portion 113 and the second label portion 123 (123) may cause a change such that the On / Off of the signal is changed due to setting or limitation of the optical device.
- the detection value of the unit cell UC becomes the fluorescence threshold value TF) (see Fig. 15 (a)).
- the fluorescence threshold value TF may be the lowest fluorescence value capable of detecting the fluorescence value through the optical device, which is determined by the setting of the optical device or the limit of the optical device.
- the detection value of the unit cell UC is reduced to less than the fluorescence threshold value TF in accordance with the linkage action in the initial state (i.e., the detection value of the unit cell UC exceeds the fluorescence threshold value TF of the optical device) ,
- the signal of the optical device may change from an on state to an off state.
- the signal of the optical device continuously detects the fluorescence value of the unit cell UC, And can be changed to an off state.
- the detection value of the unit cell UC is detected
- the coupling action of the first label portion 113 and the second label portion 123 occurs in a state where the fluorescence threshold value TF is exceeded in the region DR, It can be reduced to less than the fluorescence threshold value TF in the detection area DR (see Fig. 15 (b)).
- the detection area DR may be a wavelength band range capable of detecting the fluorescence value through the optical device determined by the setting of the optical device or the limit of the optical device.
- the fluorescence threshold value TF may be the lowest fluorescence value capable of detecting the fluorescence value through the optical device determined by setting or limitation of the optical device.
- the detection value of the unit cell UC is detected in the detection area (i.e., the detection value of the unit cell UC) in the initial state (that is, the detection value of the unit cell UC exceeds the fluorescence threshold value TF in the detection area DR of the optical device) DR to a fluorescence threshold TF, the signal of the optical device may change from an on state to an off state.
- the signal of the optical device changes the fluorescence value of the unit cell UC continuously And the state of changing to the off state can be shown.
- the first connection part 114 can prevent the amplification product for the first tag part 112 from being generated when the PCR is performed.
- the second connection unit 124 can prevent the amplification product for the second tag unit 122 from being generated when the PCR is performed.
- the first connection part 114 and the second connection part 124 may allow the first and second tag parts 112 and 122 to be maintained as a single-stranded nucleic acid even after PCR is performed.
- the first tag portion 112 and the second tag portion 122 which are single-stranded nucleic acids, can complementarily couple within specific environmental conditions.
- the first connection part 114 and the second connection part 124 allow the length of the amplification product generated in association with the nucleic acid conjugate pair 10 to be constant when PCR is performed .
- the following will be described in more detail in the following Table 1. Utilization of the nucleic acid complex pair (10) # 1-PCR.
- nucleic acid complex pair 10 The construction and general operation of the nucleic acid complex pair 10 disclosed in the present application has been described heretofore.
- the nucleic acid complex pair 10 according to the present application can be used in various fields in which nucleic acids are used.
- the nucleic acid complex pair 10 can be used as a primer for synthesis of a plasmid, preparation of a DNA chip, and DNA sequencing.
- the nucleic acid complex pair 10 can be utilized to prevent amplification for a specific base sequence in PCR.
- the nucleic acid complex pair 10 may be utilized to confirm the presence or absence of a target nucleic acid in a sample.
- the first determining unit 111 is a forward primer and the second determining unit 121 is a reverse primer, unless otherwise specified, and the first connecting unit 114 It is assumed that the first tag portion 112 and the second link portion 124 are a PCR blocker and that the first tag portion 112 and the second tag portion 122 are single strands of DNA, The fluorescence molecule and the second label portion 123 are assumed to be a quanter molecule.
- the first determination unit 111, the first connection unit 114, the first tag unit 112, the first label unit 113, the second determination unit 121, second connecting portion 124, second tag portion 122 and second label portion 123 are to be reasonably construed by the above-described substance, constitution,
- the second label portion 122 and the second label portion 123 should not be construed to be limited by the above-described assumptions.
- 16 is a diagram for explaining a nucleic acid complex 1 capable of performing PCR clamping, according to an embodiment of the present application.
- the nucleic acid complex 1 capable of performing PCR clamping may include at least a crystal section 100 and a tag section 200.
- the nucleic acid complex 1 according to an embodiment of the present application may include a crystal part 100, a tag part 200 and a connection part 400.
- the determination unit 100 may be a forward primer or a reverse primer that initiates PCR. A detailed description of this is given in Table 1.1.1.3.2 above, and no overlapping content will be described.
- the tag unit 200 may be a single-stranded body containing a nucleic acid and / or a nucleic acid analogue.
- the tag unit 200 may be a PCR clamping probe.
- the nucleotide sequence of the tag unit 200 may differ from the nucleotide sequence of the determination unit 100 by at least one. A detailed description is given in Table 1.1.2.3.2 "PCR Clamping Probe" above.
- connection unit 400 may be a compound having a predetermined length.
- the connection unit 400 may be a PCR blocker. A detailed description of this is given in Table 3.1.1.3.1 Blocker for PCR, and the contents of the duplication shall not be described.
- the nucleic acid complex (1) according to one embodiment of the present application can be used in PCR.
- 17 is a diagram for explaining a PCR step according to an embodiment of the present application.
- the PCR step may include a thermal denaturation step (S2000), an annealing step (S3000), and a polymerization reaction step (S4000).
- a PCR step may be performed on a unit cell (UC) including the nucleic acid complex (1).
- the unit cell (UC) including the nucleic acid complex (1) may be a unit cell (UC) whose temperature is changed in order to conduct a PCR reaction.
- the unit cell UC including the nucleic acid complex 1 may be a unit cell UC provided with a plurality of samples for conducting a PCR reaction.
- the unit cell UC may be a tube through which the PCR reaction proceeds.
- At least one sample may be provided in the unit cell UC.
- the unit cell UC may be provided with at least one sample used in the PCR step.
- the nucleic acid complex 1 may be included in the unit cell UC.
- Eg polymerase
- a base fragment eg, deoxynucleotide triphosphate (dNTP)
- dNTP deoxynucleotide triphosphate
- coenzyme involved in PCR eg, MgCl 2, MgSO 4
- at least one of a buffer to provide optimal pH and / or salt concentration for PCR.
- the PCR for the unit cell UC generally includes 1) denaturation step S2000 (denaturation step) for separating the double stranded DNA by regulating the temperature of the unit cell UC, 2) 3) annealing step (S3000) for controlling the temperature of the unit cell (UC) so that the primer binds to a target nucleic acid containing a specific base sequence (for example, DNA of separated single strand) (S4000) in which an amplification product for the target nucleic acid is generated at one end of a primer bound to the target nucleic acid by controlling the temperature of the target nucleic acid.
- S2000 denaturation step
- S3000 annealing step
- the thermal denaturation step (S2000), the annealing step (S3000), and the polymerization reaction step (S4000) may be sequentially and repeatedly performed.
- the temperature controlled in the thermal denaturation step (S2000) may be a temperature at which double stranded DNA is separated.
- the temperature of the unit cell (UC) in the thermal denaturation step (S2000) may be maintained at a temperature exceeding 80 ° C.
- the temperature of the unit cell (UC) in the thermal denaturation step (S2000) may be maintained at a temperature exceeding 90 ° C.
- the temperature of the unit cell (UC) in the thermal denaturation step (S2000) may be maintained in excess of 95 ° C.
- the temperature of the unit cell (UC) in the thermal denaturation step (S2000) may be maintained at 95 ° C.
- the temperature controlled in the annealing step (S3000) may be the temperature at which the primer binds to the target nucleic acid.
- the temperature of the unit cell (UC) in the annealing step (S3000) may be maintained at about 40 to 60 ° C.
- the temperature of the unit cell UC in the annealing step S3000 may be maintained at about 45 to 55 ° C.
- the temperature of the unit cell (UC) in the annealing step (S3000) may be maintained at about 50 ° C.
- the temperature controlled in the polymerization step S4000 may be a temperature at which an amplification product for the target nucleic acid is generated at one end of the primer bound to the target nucleic acid.
- the temperature of the unit cell (UC) in the polymerization reaction step (S4000) may be maintained at about 50 to 70 ° C.
- the temperature of the unit cell (UC) in the annealing step (S3000) may be maintained at about 55 to 65 ° C.
- the temperature of the unit cell UC in the annealing step S3000 may be maintained at about 60 ° C.
- nucleic acid complex 1 capable of performing PCR clamping according to an embodiment of the present application is provided in the unit cell UC (for example, a tube), the nucleic acid complex 1 ) Will be described in detail.
- 18 and 19 are diagrams for explaining the operation of the nucleic acid complex 1 capable of performing PCR clamping according to one embodiment of the present application.
- the double stranded DNA present in the unit cell UC may be denatured into single stranded DNA.
- double stranded DNA can be separated into two single stranded DNA.
- double stranded DNA formed through hydrogen bonding between two single stranded DNAs can be separated into two single stranded DNAs.
- At least one single-stranded DNA separated in the thermal denaturation step S2000 may include a target base sequence (i.e., a base sequence complementary to at least a part of the base sequence of the crystal unit 100). At least one single strand of DNA present in the unit cell (UC) may comprise the target sequence.
- a target base sequence i.e., a base sequence complementary to at least a part of the base sequence of the crystal unit 100.
- At least one single strand of DNA present in the unit cell (UC) may comprise the target sequence.
- the determination unit 100 may bind to a target nucleic acid containing a target nucleotide sequence of single strand DNA present in the unit cell (UC).
- the determination unit 100 may complementarily bind to a target nucleotide sequence of single strand DNA present in the unit cell UC.
- the determination unit 100 may complementarily bind to the target nucleotide sequence to initiate generation of an amplification product for at least a part of the target nucleic acid including the target nucleotide sequence.
- the determination unit 100 (that is, the crystal unit 100 of the nucleic acid complex 1) is a forward primer
- a separate reverse primer may be provided in the unit cell UC.
- the reverse primer may be a nucleic acid complex (1).
- the reverse primer may not be the nucleic acid complex (1).
- the reverse primer can bind to single stranded DNA having a complementary sequence to the base sequence of the reverse primer.
- the reverse primer can complementarily bind to single stranded DNA having a complementary sequence to the base sequence of the reverse primer.
- a separate forward primer may be provided in the unit cell UC.
- the forward primer may be a nucleic acid complex (1).
- the forward primer may not be the nucleic acid complex (1).
- the forward primer may bind to a single strand of DNA having a complementary sequence to the base sequence of the forward primer.
- the forward primer may complementarily bind to a single strand of DNA having a complementary sequence to the base sequence of the forward primer.
- an amplification product for at least a part of the target nucleic acid bound to the determination unit 100 may be generated with the determination unit 100 as a starting point.
- the amplification product for at least a part of the target nucleic acid can be extended to the 3'-terminal side of the crystallization part 100.
- an amplification product for at least a part of the single strand DNA to which the reverse primer is bound can be generated.
- the amplification product for at least a part of the single stranded DNA to which the reverse primer is bound can be extended to the 3'-terminal side of the reverse primer.
- the forward primer and the reverse primer are nucleic acid complexes (1)
- the first tag portion (112) is located on one side of the double- A structure in which the second tag portion 122 is positioned on the other side (one side of the double-stranded DNA and the other side) of the DNA of the first strand may be generated.
- the forward primer and the reverse primer are the nucleic acid complex (1)
- the first tag portion (112) is located at the 5'end side of the forward primer and the 5'end 2 tag portion 122 is located in the structure.
- the double stranded DNA present in the unit cell UC can be denatured into single stranded DNA.
- the double stranded DNA comprising the target nucleotide sequence may be denatured into single stranded DNA.
- the double stranded DNA comprising the target nucleotide sequence may be separated into two single stranded DNAs.
- UC there may be a similar base sequence that differs from the target base sequence by at least one base sequence.
- UC there may be a single strand of DNA and / or a single strand of DNA containing a similar base sequence.
- the similar base sequence may refer to a base sequence in which some base sequences are omitted or partial base sequences are substituted as compared with the target base sequence.
- the double stranded DNA containing the similar base sequence can be denatured into single stranded DNA.
- the double stranded DNA comprising the pseudomonucleotide sequence can be separated into two single stranded DNAs.
- the similar base sequence and the target base sequence may be contained in the same nucleic acid.
- the similar base sequence and the target base sequence may be contained in the same DNA.
- the similar base sequence and the target base sequence may be contained in different nucleic acids.
- the similar base sequence and the target base sequence may be contained in another strand of DNA.
- the determination unit 100 may bind to a target nucleic acid containing a target nucleotide sequence of single strand DNA present in the unit cell (UC).
- the determination unit 100 may complementarily bind to a target nucleotide sequence of single strand DNA present in the unit cell UC.
- the tag unit 200 can bind to a nucleic acid containing a pseudo-base sequence of single-stranded DNA present in the unit cell (UC).
- the tag unit 200 can complementarily bind to a similar base sequence of single strand DNA present in the unit cell UC.
- the tag unit 200 can prevent the determination unit 100 from being mismatched and coupled to the similar base sequence.
- the tag unit 200 can prevent the determination unit 100 from being non-specifically bound to the similar base sequence.
- an amplification product for at least a part of the target nucleic acid bound to the determination unit 100 may be generated with the determination unit 100 as a starting point.
- the amplification product for at least a part of the target nucleic acid may be extended to the 3'-terminal side of the crystallization part (100).
- the production of an amplification product for single strand DNA containing the pseudo-nucleotide sequence starting from the tag unit 200 can be prevented.
- the tag unit 200 may be connected to the connection unit 400.
- the tag unit 200 may be connected to the connection unit 400 to prevent the generation of an amplification product for a single strand DNA including the similar base sequence starting from the tag unit 200.
- the tag unit 200 is connected to the connection unit 400 to prevent generation of an amplification product for single-stranded DNA including the pseudomonucleotide sequence in the 3'-terminal direction of the tag unit 200 have.
- the H group of the 3'end of the tag unit 200 is used to be connected to the connection unit 400 so that the single strand DNA containing the similar base sequence in the 3'- It is possible to prevent the amplification product from being generated.
- connection unit 400 is made of polyethyleneglycol (PEG)
- the H of the tag unit 200 reacts with the OH groups of the connection unit 400 to form a covalent bond with the tag unit 200,
- the H group of the 3'-end of the tag unit 200 in which the nucleotide is extended has already participated in the reaction and the similar base sequence Stranded DNA can be prevented from being generated.
- the tag unit 200 in the polymerization reaction step (S4000) may be dissociated from the similar base sequence.
- the similar base sequence can be dissociated.
- the nucleic acid complex (1) according to an embodiment of the present application when used for PCR, the amplification product for the nucleic acid related to the pseudomonucleotide sequence, while generating an amplification product for the nucleic acid related to the target base sequence It may be possible to prevent generation.
- the nucleic acid complex (1) according to one embodiment of the present application when used for PCR, an advantage that the desired DNA can be more accurately amplified can be obtained.
- the nucleic acid complex 1 capable of performing PCR clamping may include the crystal part 100 and the tag part 200.
- the determination unit 100 may be a forward primer or a reverse primer that initiates a PCR reaction.
- the determination unit 100 may initiate generation of an amplification product for at least a partial region of the nucleic acid containing the target base sequence.
- the tag unit 200 may include a nucleic acid analogue.
- the tag unit 200 may be composed of a polymer of unit molecules of PNA.
- the tag unit 200 may have a base sequence different from that of the determination unit 100 at least in some regions.
- the tag unit 200 may have a base sequence in which a part of the base sequence of the determination unit 100 is omitted or a part of the base sequence is substituted.
- the tag unit 200 may be coupled to a similar base sequence.
- the tag unit 200 may be coupled to a similar base sequence to prevent binding to the similar base sequence of the crystal unit 100.
- the tag unit 200 may be coupled to a pseudomonucleotide sequence to prevent amplification of a single strand DNA containing the pseudomonucleotide sequence.
- the tag unit 200 may be composed of a unit molecule of a nucleic acid analogue, and may not be extended by a DNA polymerase. As a result, the tag unit 200 can prevent the amplification of single-stranded DNA containing the pseudo-nucleotide sequence.
- 20 is a diagram for explaining a nucleic acid complex pair 10 according to an embodiment of the present application.
- the nucleic acid conjugate pair 10 may comprise a first nucleic acid complex 110 and a second nucleic acid complex 120.
- the first nucleic acid complex 110 may include at least a first crystal portion 111 and a first tag portion 112.
- the second nucleic acid complex 120 may include at least a second crystal portion 121 and a second tag portion 122.
- the first determination unit 111 may be a forward primer or a reverse primer.
- the second determining unit 121 may be a reverse primer.
- the second determining unit 121 may be a forward primer.
- the first determining unit 111 may complementarily bind to a first target base sequence associated with a specific disease
- the second determining unit 121 may include a second target base sequence Can be complementarily combined.
- the first tag portion 112 may be complementarily coupled to the second tag portion 122.
- the second tag unit 122 may include a base sequence complementary to the first tag unit 112.
- the second tag portion 122 may include a compound that binds complementarily with the first tag portion 112.
- the nucleic acid complex pair 10 can be utilized in PCR.
- the nucleic acid complex pair 10 may be used in PCR to perform functions of a forward primer and a reverse primer.
- the first nucleic acid complex 110 may be used as a forward primer and the second nucleic acid complex 120 may be used as a reverse primer.
- the first nucleic acid complex 110 may be used as a reverse primer
- the second nucleic acid complex 120 may be used as a forward primer.
- the nucleic acid complex pair 10 When the nucleic acid complex pair 10 is used in PCR, the nucleic acid complex pair 10 may need to be provided in a unit cell (UC) in which PCR is to be performed.
- UC unit cell
- the nucleic acid conjugate pair 10 When the nucleic acid conjugate pair 10 is provided in the unit cell UC, the nucleic acid conjugate pair 10 may be a state in which the first tag portion 112 and the second tag portion 122 are complementarily coupled to each other. have.
- the unit cell UC may be provided with a nucleic acid complex pair 10 in which a first tag portion 112 and a second tag portion 122 are complementarily coupled to each other.
- the first tag portion 112 and the second tag portion 122 may be synthesized in a complementary manner in the process of synthesizing the nucleic acid conjugate pair 10.
- the first tag portion 112 and the second tag portion 122 may be complementarily combined with each other.
- 21 is a diagram for explaining a pairing operation of the nucleic acid complex pair 10 according to an embodiment of the present application.
- the pairing step (S1000) may be performed before the PCR proceeds.
- the pairing step (S1000) may be performed prior to the thermal denaturation step (S2000).
- the pairing step S1000 may be a step of inducing a complementary combination of the first tag portion 112 and the second tag portion 122.
- the complementary coupling of the first and second tag portions 112 and 122 of the nucleic acid complex pair 10 included in the unit cell UC is induced .
- the temperature adjusted in the pairing step S1000 may be a temperature at which the first tag portion 112 and the second tag portion 122 are complementarily coupled.
- the temperature adjusted in the pairing step S1000 may be an annealing temperature in a region where the first tag portion 112 and the second tag portion 122 are complementarily coupled to each other.
- the nucleic acid complex pair 10 can be subjected to PCR.
- the nucleic acid complex pair (10) can be thermally denaturated (S2000).
- the nucleic acid complex pair 10 can be subjected to PCR in the order of thermal denaturation step S2000, annealing step S3000, and polymerization reaction step S4000.
- the nucleic acid complex pair 10 can be subjected to PCR at least one cycle with one cycle of a thermal denaturation step S2000, an annealing step S3000, and a polymerization reaction step S4000.
- the solution to the unit cell UC containing the nucleic acid complex pair 10 after the pairing step S1000 may be dispensed.
- the solution to the unit cell UC containing the nucleic acid complex pair 10 after the pairing step S1000 may be dispensed into a smaller unit (e.g., a tube or a well).
- a smaller unit e.g., a tube or a well.
- 22 is a diagram for explaining a nucleic acid complex pair 10 according to an embodiment of the present application.
- the nucleic acid conjugate pair 10 may comprise a first nucleic acid complex 110 and a second nucleic acid complex 120.
- the first nucleic acid complex 110 may include at least a first crystal portion 111, a first tag portion 112, and a first label portion 113.
- the second nucleic acid complex 120 may include at least a second crystal portion 121, a second tag portion 122, and a second label portion 123.
- the first determination unit 111 may be a forward primer or a reverse primer.
- the second determining unit 121 may be a reverse primer.
- the second determining unit 121 may be a forward primer.
- the first determining unit 111 may complementarily bind to a first target base sequence associated with a specific disease
- the second determining unit 121 may include a second target base sequence Can be complementarily combined.
- the first tag portion 112 may be complementarily coupled to the second tag portion 122.
- the second tag unit 122 may include a base sequence complementary to the first tag unit 112.
- the second tag portion 122 may include a compound that binds complementarily with the first tag portion 112.
- the first label portion 113 and the second label portion 123 may perform a linking operation.
- the first label portion 113 is a fluorescent molecule
- the second label portion 123 may be a quan- tizer molecule that functions to absorb or convert light emitted from the first label portion 113.
- first label portion 113 and the second label portion 123 are linked or not may be related to whether or not the first tag portion 112 and the second tag portion 122 are coupled. For example, whether or not the first label portion 113 and the second label portion 123 are linked can be determined by whether or not the first tag portion 112 and the second tag portion 122 are coupled to each other .
- the solution to the unit cell UC including the nucleic acid complex pair 10 may be dispensed after the pairing step S1000, as in the above-described embodiment. After the pairing step (S1000), the solution to the unit cell (UC) containing the nucleic acid complex pair (10) can be dispensed into smaller units.
- the physical characteristics of the smaller unit cell UC before the temperature control and the physical characteristics of the smaller unit cell UC after the temperature control Physical properties may vary. For example, when optical characteristics for the smaller unit cell (UC) are detected through an optical device, a detection value before the unit cell (UC) whose temperature has been adjusted to raise the temperature increases the temperature The temperature of the unit cell UC may be smaller than the detection value after the temperature of the unit cell UC is adjusted.
- the first crystallization part 111 and the second crystallization part 121 can specifically bind to each other.
- the nucleic acid complex pair 10 includes a first target base sequence that is complementary to the first crystal section 111 and a second target base sequence that is complementary to the second crystal section 121 (I. E., An associated substance). ≪ / RTI > The first determining unit 111 and the second determining unit 121 can specifically bind to a nucleic acid including a first target base sequence and a second target base sequence.
- the first tag portion 112 and the second tag portion 122 can be complementarily combined.
- the shape of the structure connected to the first and second crystallization parts 111 and 121 can be changed according to the complementary coupling between the first and second tag parts 112 and 122 .
- the first tag portion 112 and the second tag portion 122 are connected to each other by a complementary coupling between the first and second tag portions 112 and 121, Can form a secondary structure.
- the structure connected to the first crystal portion 111 and the second crystal portion 121 has a similar hairpin structure .
- the shape of the secondary structure formed by the complementary combination of the first tag portion 112 and the second tag portion 122 may be a shape of the first tag portion 112 and the second tag portion 122, (122).
- the tag portion 200 has been described in detail in the above table 2.2, and thus a duplicate description will be omitted.
- FIGS. 23 and 24 are views for explaining the formation of a secondary structure of a structure coupled with the first crystallization part 111 and the second crystallization part 121, according to an embodiment of the present application.
- the first determining unit 111 may bind to a nucleic acid containing a first target base sequence.
- the second determining unit 121 may bind to the nucleic acid containing the second target base sequence.
- the first determining unit 111 and the second determining unit 121 may bind to a nucleic acid including a first target base sequence and a second target base sequence.
- the first tag portion 112 may be complementarily coupled to the second tag portion 122.
- the first tag portion 112 and the second tag portion 122 are arranged in the order of the base sequence of the region adjacent to the first determination portion 111 of the first tag portion 112 and the second base portion 122 of the second tag portion 122 121 may have a base sequence so that the base sequence of the isolated region is complementary to the base sequence.
- the first tag portion 112 and the second tag portion 122 are connected to the base sequence of the region adjacent to the first connection portion 114 of the first tag portion 112 and the second connection portion 124 of the second tag portion 122, And the base sequence of the isolated region may have a nucleotide sequence to make a complementary binding.
- the first tag portion 112 and the second tag portion 122 may have a base sequence capable of binding in the form as shown in FIG. 12 (a).
- the nucleic acid comprising the first target base sequence and the second target base sequence may form a pseudo-circular structure.
- the nucleic acid including the first target base sequence and the second target base sequence may be complementarily combined with the first and the second determinants 111 and 121.
- the first tag portion 112 and the second tag portion 122 are complementarily combined with each other, the first target base sequence and the second target base sequence, which are connected to the first determiner 111 and the second determiner 121, May form a pseudo-circular structure.
- the base sequence of the region adjacent to the first determining unit 111 of the first tag unit 112 and the nucleotide sequence of the region separated from the second determining unit 121 of the second tag unit 122 are complementary
- the first tag portion 112 and the second tag portion 122 are complementarily combined with each other in the form of a first target portion sequence and a second target portion sequence connected to the first determination portion 111 and the second determination portion 121
- the nucleic acid containing the target base sequence can form a pseudo-circular structure.
- pseudo-circular structure means that at least a part of the loop structure formed to have an arbitrary curvature is formed of double strands, and at least a part of the loop structure is opened so as not to form a complete circular shape have.
- nucleic acids connected to the first and second crystallization parts 111 and 121 are aligned in a complementary combination of the first and second tag parts 112 and 122, It can be determined whether to form a pseudo-circular structure. It is possible to determine whether or not the first label portion 113 and the second label portion 123 are connected to each other in accordance with the complementary combination of the first tag portion 112 and the second tag portion 122. Whether or not the first label portion 113 and the second label portion 123 perform the linkage operation depends on whether or not the nucleic acid connected to the first crystal portion 111 and the second crystal portion 121 forms a pseudo-circular structure It can be different.
- the first determining unit 111 may bind to a nucleic acid containing a first target base sequence.
- the second determining unit 121 may bind to the nucleic acid containing the second target base sequence.
- the first determining unit 111 and the second determining unit 121 may bind to a nucleic acid including a first target base sequence and a second target base sequence.
- the first tag portion 112 may be complementarily coupled to the second tag portion 122.
- the first tag portion 112 and the second tag portion 122 are arranged in the order of the base sequence of the region adjacent to the first determination portion 111 of the first tag portion 112 and the second base portion 122 of the second tag portion 122 121) may have a base sequence so that the base sequence of the adjacent region is complementary to the base sequence.
- the first tag portion 112 and the second tag portion 122 are connected to the base sequence of the region adjacent to the first connection portion 114 of the first tag portion 112 and the second connection portion 124 of the second tag portion 122, And the nucleotide sequence of the adjacent region may have a base sequence so as to make a complementary binding.
- the first tag portion 112 and the second tag portion 122 may have a base sequence capable of binding in the form as shown in FIG. 12 (b).
- the nucleic acid comprising the first target base sequence and the second target base sequence may form a similar hairpin structure.
- the nucleic acid including the first target base sequence and the second target base sequence may be complementarily combined with the first and the second determinants 111 and 121.
- the first tag portion 112 and the second tag portion 122 are complementarily combined with each other, the first target base sequence and the second target base sequence, which are connected to the first determiner 111 and the second determiner 121, May form a pseudo-circular structure.
- the base sequence of the region adjacent to the first determining unit 111 of the first tag unit 112 and the nucleotide sequence of the region adjacent to the second determining unit 121 of the second tag unit 122 are complementary to each other
- the first target base sequence and the second target portion 112 which are connected to the first and second determination portions 111 and 121
- a nucleic acid comprising a nucleotide sequence can form a similar hairpin structure.
- similar hairpin structure refers to a structure in which at least some regions of a loop structure formed to have an arbitrary curvature are double-stranded, and a base sequence connected to one end of each single strand of the double- And a stem structure connected to the stem structure may be formed.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (17)
- 제1 결정부 및 제2 태그부를 포함하는 제1 핵산 복합체; 및 제2 결정부 및 제2 태그부를 포함하는 제2 핵산 복합체;를 포함하는 핵산 복합체 페어에 있어서,상기 제1 결정부는, 제1 타겟 DNA에 대한 포워드 프라이머를 포함하고,상기 제2 결정부는, 상기 제1 타겟 DNA에 대한 리버스 프라이머를 포함하며,상기 제1 태그부는 상기 제2 태그부의 염기 서열에 상보적인 염기 서열을 포함하고,상기 제2 태그부는 상기 제1 태그부의 염기 서열에 상보적인 염기 서열을 포함하는,핵산 복합체 페어.
- 제1 항에 있어서,상기 제1 결정부는, DNA(Deoxyribonucleic acid), RNA(Ribonucleic acid), PNA(Peptide nucleic acid), LNA(Locked Nucleic Acid), BNA(Bridged nucleic acid), HNA(Hexose nucleic acid), GNA(Glycol nucleic acid), TNA(Threose nucleic acid), CeNA(cyclohexene nucleic acid) 또는 이들의 조합으로 이루어지고,상기 제2 결정부는, DNA(Deoxyribonucleic acid), RNA(Ribonucleic acid), PNA(Peptide nucleic acid), LNA(Locked Nucleic Acid), BNA(Bridged nucleic acid), HNA(Hexose nucleic acid), GNA(Glycol nucleic acid), TNA(Threose nucleic acid), CeNA(cyclohexene nucleic acid) 또는 이들의 조합으로 이루어진,핵산 복합체 페어.
- 제1 항에 있어서,상기 제1 태그부는, DNA(Deoxyribonucleic acid), RNA(Ribonucleic acid), PNA(Peptide nucleic acid), LNA(Locked Nucleic Acid), BNA(Bridged nucleic acid), HNA(Hexose nucleic acid), GNA(Glycol nucleic acid), TNA(Threose nucleic acid), CeNA(cyclohexene nucleic acid) 또는 이들의 조합으로 이루어지고,상기 제2 태그부는, DNA(Deoxyribonucleic acid), RNA(Ribonucleic acid), PNA(Peptide nucleic acid), LNA(Locked Nucleic Acid), BNA(Bridged nucleic acid), HNA(Hexose nucleic acid), GNA(Glycol nucleic acid), TNA(Threose nucleic acid), CeNA(cyclohexene nucleic acid) 또는 이들의 조합으로 이루어진,핵산 복합체 페어.
- 제1 항에 있어서,상기 제1 핵산 복합체는 제1 라벨부를 포함하고,상기 제2 핵산 복합체는 제2 라벨부를 포함하며,상기 제1 라벨부는 상기 제2 라벨부에 에너지를 제공할 수 있는,핵산 복합체 페어.
- 제2 항에 있어서,상기 제1 라벨부는, FAM, JOE, TET, HEX, VIC, Oregon Green®, TAMRA, ROX, Cyanine-3, Cyanine-3.5, Cyanine-5, Cyanine-5.5, 에쿼린(Aequorin) 및 청색 형광 단백질(Cyan Fluorescent Protein, CFP) 중 적어도 하나를 포함하는,핵산 복합체 페어.
- 제5 항에 있어서,상기 제2 라벨부는,상기 제1 라벨부로부터 방출되는 제1광을 수용하여, 제2 광으로 변환하는 물질 또는 상기 제1 라벨부로부터 방출되는 상기 제1광을 흡수하는 물질인,핵산 복합체 페어.
- 제4 항에 있어서,상기 제1 태그부와 상기 제2 태그부가 상보적으로 결합할 때, 상기 제1 라벨부는 상기 제2 라벨부에 에너지를 제공할 수 있는,핵산 복합체 페어.
- 제4 항에 있어서,상기 제1 태그부는 상기 제1 결정부 및 상기 제1 라벨부 사이에 위치되고,상기 제2 태그부는 상기 제2 결정부 및 상기 제2 라벨부 사이에 위치되는,핵산 복합체 페어.
- 제4 항에 있어서,상기 제1 라벨부는 상기 제1 결정부 및 상기 제1 태그부 사이에 위치되고,상시 제2 태그부는 상기 제2 결정부 및 상기 제2 라벨부 사이에 위치되는,핵산 복합체 페어.
- 제1 항에 있어서,상기 제1 결정부 및 상기 제1 태그부 사이에 제1 연결부가 위치되고,상기 제2 결정부 및 상기 제2 태그부 사이에 제2 연결부가 위치되는,핵산 복합체 페어.
- 제10 항에 있어서,상기 제1 연결부는, 상기 제1 태그부에 대한 증폭산물의 생성을 방지하기위한 PCR 블로커를 포함하고,상기 제2 연결부는, 상기 제2 태그부에 대한 증폭산물의 생성을 방지하기위한 PCR 블로커를 포함하는,핵산 복합체 페어.
- 제1 항에 있어서,상기 핵산 복합체 페어는 핵산서열증폭반응(PCR)을 수행하는데 이용되고,상기 핵산서열증폭반응은, 상기 제1 타겟 DNA의 적어도 일부 서열을 증폭시키기 위해 수행되는,핵산 복합체 페어.
- 제12 항에 있어서,상기 핵산 복합체 페어는 디지털 PCR을 수행하는데 이용되는,핵산 복합체 페어.
- 제1 항에 있어서,상기 제1 태그부의 염기 서열의 길이는, 상기 제2 태그부의 염기 서열의길이에 비해 짧은,핵산 복합체 페어.
- 제1 항에 있어서,상기 제1 태그부의 염기 서열 중 일부 염기 서열은,상기 제1 결정부의 염기 서열 중 일부 염기 서열 또는 상기 제2 결정부의 염기 서열 중 일부 염기 서열과 동일한,핵산 복합체 페어.
- 제1 항에 따른 핵산 복합체 페어를 포함하는 PCR용 키트.
- 제16 항에 있어서,DNA 중합 효소, PCR에 관여하는 조효소, pH 및/또는 염농도를 조절하기위한 완충용액(buffer) 중 적어도 하나가 더 포함되는,PCR용 키트.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018308331A AU2018308331A1 (en) | 2017-07-25 | 2018-07-25 | Nucleic acid complex pair, competitive construct, and pcr kit using the same |
CN201880062251.9A CN111278989A (zh) | 2017-07-25 | 2018-07-25 | 核酸复合物对、竞争性结构体和使用二者的pcr试剂盒 |
EP18839013.2A EP3660171A4 (en) | 2017-07-25 | 2018-07-25 | NUCLEIC ACID COMPLEX PAIR, COMPETITIVE STRUCTURE AND PCR KIT WITH THESE |
CA3071088A CA3071088A1 (en) | 2017-07-25 | 2018-07-25 | Nucleic acid complex pair, competitive construct, and pcr kit using the same |
US16/752,277 US11066700B2 (en) | 2017-07-25 | 2020-01-24 | Nucleic acid complex pair, competitive construct, and PCR kit using the same |
US17/322,737 US20210292813A1 (en) | 2017-07-25 | 2021-05-17 | Nucleic acid complex pair, competitive construct, and pcr kit using the same |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762536898P | 2017-07-25 | 2017-07-25 | |
US62/536,898 | 2017-07-25 | ||
US201762580335P | 2017-11-01 | 2017-11-01 | |
US62/580,335 | 2017-11-01 | ||
KR1020180007355A KR101899371B1 (ko) | 2017-07-25 | 2018-01-19 | 핵산 복합체 페어, 핵산 복합체 페어를 포함하는 pcr용 키트, 및 핵산 복합체 페어를 이용한 타겟 검출 방법 |
KR10-2018-0007355 | 2018-01-19 | ||
KR1020180014739A KR101899372B1 (ko) | 2017-07-25 | 2018-02-06 | 핵산 복합체 페어를 포함하는 pcr용 키트 및 이의 용도 |
KR10-2018-0014739 | 2018-02-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/752,277 Continuation US11066700B2 (en) | 2017-07-25 | 2020-01-24 | Nucleic acid complex pair, competitive construct, and PCR kit using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019022520A1 true WO2019022520A1 (ko) | 2019-01-31 |
Family
ID=63721923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/008444 WO2019022520A1 (ko) | 2017-07-25 | 2018-07-25 | 핵산 복합체 페어, 경쟁 구조체, 이를 이용한 pcr 키트 |
Country Status (7)
Country | Link |
---|---|
US (3) | US11091802B2 (ko) |
EP (1) | EP3660171A4 (ko) |
KR (10) | KR101899371B1 (ko) |
CN (1) | CN111278989A (ko) |
AU (1) | AU2018308331A1 (ko) |
CA (1) | CA3071088A1 (ko) |
WO (1) | WO2019022520A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7066540B2 (ja) * | 2018-06-14 | 2022-05-13 | 株式会社日立製作所 | デジタルpcrの測定方法および測定装置 |
KR20240028084A (ko) | 2022-08-24 | 2024-03-05 | 주식회사 멀티렉스 | 표지자가 결합된 태그 프로브 및 이의 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020197611A1 (en) * | 2001-06-21 | 2002-12-26 | Chagovetz Alexander Michael | Method for real-time detection and quantification of nucleic acid sequences using fluorescent primers |
US20080064033A1 (en) * | 2004-09-24 | 2008-03-13 | Universitaet Bern | Molecular Beacons |
US20100129792A1 (en) * | 2007-02-06 | 2010-05-27 | Gerassimos Makrigiorgos | Direct monitoring and pcr amplification of the dosage and dosage difference between target genetic regions |
US20110207131A1 (en) * | 2008-07-31 | 2011-08-25 | Guoliang Fu | Multiplex amplification and detection |
KR20120021262A (ko) * | 2010-08-30 | 2012-03-08 | 삼성테크윈 주식회사 | 안정화된 프로브를 이용한 실시간 pcr 검출 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432642B1 (en) | 1999-01-15 | 2002-08-13 | Pe Corporation (Ny) | Binary probe and clamp composition and methods for a target hybridization detection |
CN1348096A (zh) | 2000-10-10 | 2002-05-08 | 栾国彦 | 一种均相特异性检测核酸的探针及应用方法 |
EP2789689B1 (en) | 2009-06-29 | 2016-04-27 | Luminex Corporation | Chimeric primers with hairpin conformations and methods of using same |
CN102242211A (zh) * | 2011-07-08 | 2011-11-16 | 无锡锐奇基因生物科技有限公司 | 检测突变核酸序列的方法及试剂盒 |
KR20130008283A (ko) | 2011-07-12 | 2013-01-22 | 주식회사 파나진 | 평행결합 구조의 이중 혼성화 pna 프로브 시스템을 포함하는 실시간 다중 중합효소 연쇄반응에 의한 결핵균 및 비결핵 항산균의 동시 검출용 조성물 및 이를 이용한 검출 방법 |
WO2013039228A1 (ja) * | 2011-09-14 | 2013-03-21 | 日本碍子株式会社 | 標的核酸の検出方法 |
US9074249B2 (en) | 2012-06-04 | 2015-07-07 | New England Biolabs, Inc. | Detection of amplification products |
ES2662825T3 (es) * | 2013-02-25 | 2018-04-09 | Seegene, Inc. | Detección de variación de nucleótido en una secuencia de ácidos nucleicos diana |
GB2515990B (en) | 2013-03-06 | 2016-05-04 | Lgc Genomics Ltd | Polymerase chain reaction detection system |
GB2512631A (en) | 2013-04-03 | 2014-10-08 | Rupert Maxwell Gaut | Quantitative detection of specific nucleic acid sequences |
US11117113B2 (en) | 2015-12-16 | 2021-09-14 | Fluidigm Corporation | High-level multiplex amplification |
-
2018
- 2018-01-19 KR KR1020180007355A patent/KR101899371B1/ko active IP Right Grant
- 2018-02-06 KR KR1020180014739A patent/KR101899372B1/ko active IP Right Grant
- 2018-07-25 KR KR1020180086860A patent/KR102144163B1/ko active Application Filing
- 2018-07-25 CN CN201880062251.9A patent/CN111278989A/zh active Pending
- 2018-07-25 EP EP18839013.2A patent/EP3660171A4/en active Pending
- 2018-07-25 US US16/045,566 patent/US11091802B2/en active Active
- 2018-07-25 CA CA3071088A patent/CA3071088A1/en active Pending
- 2018-07-25 WO PCT/KR2018/008444 patent/WO2019022520A1/ko unknown
- 2018-07-25 AU AU2018308331A patent/AU2018308331A1/en not_active Abandoned
- 2018-08-21 KR KR1020180097147A patent/KR102130167B1/ko active IP Right Grant
- 2018-08-21 KR KR1020180097145A patent/KR102130165B1/ko active IP Right Grant
- 2018-08-21 KR KR1020180097146A patent/KR20190011704A/ko not_active Application Discontinuation
- 2018-08-21 KR KR1020180097144A patent/KR102144166B1/ko active IP Right Grant
- 2018-09-10 KR KR1020180108001A patent/KR20190011706A/ko active Application Filing
- 2018-09-10 KR KR1020180108002A patent/KR102361993B1/ko active IP Right Grant
-
2020
- 2020-01-24 US US16/752,277 patent/US11066700B2/en active Active
- 2020-08-06 KR KR1020200098647A patent/KR20200096893A/ko active Application Filing
-
2021
- 2021-05-17 US US17/322,737 patent/US20210292813A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020197611A1 (en) * | 2001-06-21 | 2002-12-26 | Chagovetz Alexander Michael | Method for real-time detection and quantification of nucleic acid sequences using fluorescent primers |
US20080064033A1 (en) * | 2004-09-24 | 2008-03-13 | Universitaet Bern | Molecular Beacons |
US20100129792A1 (en) * | 2007-02-06 | 2010-05-27 | Gerassimos Makrigiorgos | Direct monitoring and pcr amplification of the dosage and dosage difference between target genetic regions |
US20110207131A1 (en) * | 2008-07-31 | 2011-08-25 | Guoliang Fu | Multiplex amplification and detection |
KR20120021262A (ko) * | 2010-08-30 | 2012-03-08 | 삼성테크윈 주식회사 | 안정화된 프로브를 이용한 실시간 pcr 검출 |
Non-Patent Citations (4)
Title |
---|
HUANG, Q. ET AL.: "Multiplex Fluorescence Melting Curve Analysis for Mutation Detection with Dual-labeled, Self-quenched Probes", PLOS ONE, vol. 6, no. 4, April 2011 (2011-04-01), pages 1 - 9, XP055021038 * |
NAVARRO, E. ET AL.: "Real-time PCR Detection Chemistry", CLINICA CHIMICA ACTA, vol. 439, 2015, pages 231 - 250, XP055492527 * |
OLIVIER, M.: "The Invader Assay for SNP Genotyping", MUTATION RESEARCH, vol. 573, 2005, pages 103 - 110, XP027632671 * |
See also references of EP3660171A4 * |
Also Published As
Publication number | Publication date |
---|---|
KR101899372B1 (ko) | 2018-09-17 |
KR20190011705A (ko) | 2019-02-07 |
US11066700B2 (en) | 2021-07-20 |
KR20190011700A (ko) | 2019-02-07 |
CA3071088A1 (en) | 2019-01-31 |
AU2018308331A1 (en) | 2020-02-27 |
US11091802B2 (en) | 2021-08-17 |
KR101899371B1 (ko) | 2018-10-29 |
US20190330679A1 (en) | 2019-10-31 |
KR20200096893A (ko) | 2020-08-14 |
KR20190011703A (ko) | 2019-02-07 |
CN111278989A (zh) | 2020-06-12 |
US20210292813A1 (en) | 2021-09-23 |
KR102144163B1 (ko) | 2020-08-18 |
KR20190011704A (ko) | 2019-02-07 |
EP3660171A1 (en) | 2020-06-03 |
KR20190011706A (ko) | 2019-02-07 |
EP3660171A4 (en) | 2021-04-28 |
KR102144166B1 (ko) | 2020-08-18 |
KR20190011707A (ko) | 2019-02-07 |
KR20190011702A (ko) | 2019-02-07 |
US20200232012A1 (en) | 2020-07-23 |
KR102130165B1 (ko) | 2020-07-09 |
KR102361993B1 (ko) | 2022-03-10 |
KR102130167B1 (ko) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017188669A2 (ko) | 절단된 상보적인 태그 절편을 이용한 표적 핵산 서열 검출 방법 및 그 조성물 | |
WO2021086083A2 (ko) | CRISPR/Cas12f1 시스템 효율화를 위한 엔지니어링 된 가이드 RNA 및 그 용도 | |
WO2011149255A2 (en) | Modified rnase h and detection of nucleic acid amplification | |
WO2020218831A1 (ko) | 신규한 등온 단일 반응용 프로브 세트 및 이의 용도 | |
WO2019009682A2 (ko) | 표적 특이적 crispr 변이체 | |
WO2019022520A1 (ko) | 핵산 복합체 페어, 경쟁 구조체, 이를 이용한 pcr 키트 | |
WO2015199387A2 (ko) | 가용성 단백질 발현량 및 활성이 증대된 헬리코박터 파일로리 유래 α-1,3 푸코실 전달효소의 유전자와 단백질 및 α-1,3 푸코실올리고당 생산에의 응용 | |
WO2011157222A1 (zh) | 淋巴瘤融合基因的联合检测方法及其诊断试剂盒 | |
WO2022220503A1 (ko) | Crispr 시스템을 이용한 유전자 발현 조절 시스템 | |
WO2018208133A1 (ko) | 고순도 뉴클레오타이드 획득 방법 및 장치 | |
WO2018139826A1 (ko) | Dna 메틸화를 이용한 연령 예측 방법 | |
WO2022075813A1 (ko) | Crispr/cas12f1 시스템 효율화를 위한 엔지니어링 된 가이드 rna 및 그 용도 | |
WO2020105873A1 (ko) | 인간 알파코로나바이러스 전장유전체 증폭을 통한 진단키트 및 전장 유전체 서열 확인 방법 | |
WO2011120398A1 (zh) | 白血病融合基因的联合检测方法及其诊断试剂盒 | |
WO2020235974A2 (ko) | 단일염기 치환 단백질 및 이를 포함하는 조성물 | |
WO2022075808A1 (ko) | Crispr/cas12f1 시스템 효율화를 위한 u-rich tail을 포함하는 엔지니어링 된 가이드 rna 및 그 용도 | |
WO2020122679A1 (en) | Method for detecting a target analyte in a sample using an s-shaped function for a slope data set | |
WO2023059115A1 (ko) | 유전자 편집을 위한 target 시스템 및 이의 용도 | |
WO2015167087A1 (ko) | Dna 복제수 변이를 이용한 강직성 척추염 발병 위험도 예측 방법 | |
WO2011139032A2 (ko) | 표적 유전자의 다양한 변이가 존재하는 유전자 영역을 증폭하기 위한 프라이머 조성물 | |
WO2022191485A1 (ko) | 리포터 및 이의 용도 | |
WO2019135477A2 (ko) | 다복제유전자를 이용한 쯔쯔가무시병의 진단방법 | |
WO2023075569A1 (ko) | 분할된 t7 프로모터를 이용한 등온 단일 반응용 프로브 세트 및 이의 용도 | |
EP4204586A1 (en) | Method for positive control reaction using pre-positive control composition | |
WO2023195780A1 (en) | Method for detecting three target nucleic acids in sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18839013 Country of ref document: EP Kind code of ref document: A1 |
|
WD | Withdrawal of designations after international publication |
Designated state(s): KR |
|
ENP | Entry into the national phase |
Ref document number: 3071088 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018308331 Country of ref document: AU Date of ref document: 20180725 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018839013 Country of ref document: EP Effective date: 20200225 |